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Abstract
Rotsinger, Joseph Edward. M.S. Department of Biochemistry and Molecular Biology M.S
Program, Wright State University, 2012. Exploration of YPEL3 response to hormones
and ability to induce senescence.

p53 activation through different cellular senescence pathways can trigger cell cycle
arrest via regulation of p53 target genes. One such target gene is YPEL3 which is
expressed upon binding of tumor suppressor protein p53 at its p53 binding sites (Kelley,
2010). The ability of p53 to induce YPEL3 gene expression led to the discovery that
YPEL3 is one of several p53 target genes which induce cellular senescence (Kelley, 2010).
Additionally YPEL3 can be regulated independently of p53 by estrogen signaling through
estrogen receptor α (Tuttle, 2011). The loss of estrogen receptor α or removal of
estrogen induces YPEL3 gene expression and leads to cellular senescence, indicating
that estrogen bound to estrogen receptor α represses YPEL3 gene expression (Tuttle,
2011). Although YPEL3 induction results in cellular senescence the mechanism by which
YPEL3 elicits cellular senescence is not well understood. It is also unknown if other
steroid hormones, such as testosterone play a role in regulating YPEL3 gene expression
To further understand hormone regulation of YPEL3 the first part of this thesis tested
if testosterone regulates YPEL3 gene expression in MCF7 breast cancer cells and LnCAP
prostate cancer cells. Like MCF7 breast cancer cells, LnCAPs cultured in the absence of
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steroid hormones induced YPEL3 expression indicating that YPEL3 gene expression in
LnCAPs is repressed by steroid hormones. This induction of YPEL3 expression was
blocked by the addition of testosterone to LnCAP cells. In contrast the addition of
testosterone to steroid deprived MCF7 cells resulted in YPEL3 induction. Based on the
results in LnCAP prostate cancer cells and MCF7 breast cancer cells it appears that
testosterones effect on YPEL3 gene expression is tissue specific.
In part two of this thesis MCF7 and IMR90 cells were employed to determine if over
expression of YPEL3 leads to increased reactive oxygen species (ROS) levels. First an
optimized method for detecting reactive oxygen species levels in breast cancer cells
using DCFDA was developed. Utilizing this method, MCF7 human breast cancer cells
harboring a Tet-On system expressing YPEL3 induced with tetracycline did not show
increased levels of reactive oxygen species over LacZ expressing MCF7 cells.
Additionally Infecting MCF7 cells with lentivirus expressing YPEL3 and probing with
DCFDA showed no increase of ROS levels. Alternatively IMR90 primary diploid human
fibroblasts containing a normal repertoire of genes and fully functional pathways were
infected with lentivirus expressing YPEL3 and also did not show an increase in ROS
levels. These results suggest that YPEL3 activates senescence in a ROS independent
manner.
The third part of this thesis was to identify YPEL3 interacting proteins. Epitope
tagged YPEL3 proteins obtained from MCF7 tetracycline responsive cells expressing
YPEL3 were captured from cell extracts by co-immunoprecipitation, followed by elution
and denaturing. Denatured proteins were separated by SDS-Page gel electrophoresis
v

and potential protein bands excised for composition analysis by LC/MS/MS. LC/MS/MS
analysis identified potential proteins that interact with YPEL3.
The cumulative findings of this thesis were designed to aid in the understanding of
YPEL3 regulation by testosterone and to assist in locating potential downstream targets
of YPEL3 that may lead to senescence.
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I. Introduction
Compiled data from 1970 to 2002 showed heart disease as the leading cause of death
in the United States, with cancer ranking second but predicted to overtake heart disease
as the leading cause of death (Ahmedin, 2005). This is not due to an increase in the
number of cancer related deaths; rather it is due to a 52.1% reduction in the number of
deaths from heart disease, but only a decline of 2.7% in cancer related deaths
(Ahmedin, 2005). In 2012 cancer is still projected to be the second leading cause of
death in the United States (Siegel, 2012). It is estimated that 1,638,910 new invasive
cancer cases will be diagnosed with 577,190 cancer related deaths being projected
(Siegel, 2012). In males and females prostate cancer and breast cancer both have the
second highest number of diagnoses respectively, behind only skin cancer (Siegel, 2012).
Breast cancer is projected to account for 229,060 cases with the mortality rate
projection being 39,920 in both sexes, with males accounting for 1% of new cases as
well as deaths (Siegel, 2012). Prostate cancer is projected to account for 241,740 new
cases and 28,170 deaths (Siegel, 2012). With nearly 70,000 projected deaths from
breast or prostate cancer it becomes even more important to understand the molecular
basis of the disease and to improve our ability to prevent and detect these cancers
earlier.

1

Breast Cancer
Critical to early detection of breast cancer is self or clinical breast exams to identify
masses that may be forming. Growth progression of a cancerous mass is dependent on
the level of the growth stimulating hormone estrogen, and the presence or absence of
its receptors. Follicle stimulating hormone is the major stimulator of estrogen
production, which occurs mainly in the placenta, corpus luteum and developing follicles
in the ovaries. Also, to a lesser extent it is produced in granulosa cells of the ovaries,
adrenal glands, fat cells and the breasts. After synthesis estrogen diffuses into cells
where it binds one of two types of nuclear hormone receptors in the cytoplasm and is
subsequently translocated into the nucleus to impart growth stimulating effects by
interacting with estrogen response elements of genes. Nuclear hormone receptors are
ligand activated transcription factors that bind to specific DNA sequences known as
hormone response elements and are able to repress or activate transcription of genes
harboring hormone response elements. There are two estrogen binding nuclear
hormone receptors, estrogen receptor α (ER-α) and estrogen receptor β (ER-β), which
share a high level of sequence homology overall (Dutertre, 2000). However, they have
very little sequence homology at one of the two activation of function domains (AF-1)
which is critical to ER-α’s ability to recruit co-regulatory protein complexes for gene
expression (Hall, 1999) ER-β contains a repressor at AF-1 that antagonizes ER-α function
through dimerization of ER-α and ER-β (Hall, 1999 and Dutertre, 2000). ER-β also causes
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competitive repression of ER-α by blocking the ability of ER-α to bind hormone response
elements of target genes (Leung, 2007). Another unique characteristic is their different
gene expression patterns (Couse, 1997). For example, estrogen receptor α is highly
expressed in breast tissue, whereas in prostate tissue estrogen receptor β is the main
receptor expressed (Couse, 1997). The most extensively studied estrogen receptor is
ER-α, which imparts pro-growth effects by inducing expression of genes that positively
regulate cell cycle progression and cell division while repressing genes that are growth
suppressive (Preston-Martin, 1990). ER-β is the other nuclear estrogen receptor,
however its function is not fully known. ER-β has gone unnoticed until it was recently
discovered that it may play a role in preventing metastasis of cancerous cells and may
also have antiproliferative functions (Roy, 2011). This correlates with findings that
suggest ER-β positive breast cancers have a better prognosis than ER-β negative breast
cancers (Leung, 2007). ER-β also has the ability to increase cell sensitivity to selective
estrogen receptor modulators (SERMs) by mediating their antiestrogenic properties.
SERMs elicit an antiestrogenic effect when bound to estrogen receptors by reducing the
ability of estrogen to signal cell proliferation. When ER-β binds SERMs it can
homodimerize with ER-α and modulate ER-α’s ability to induce proliferation (Leung,
2007). The levels of ER-β expressed can also be used as a marker to determine how well
cancer may respond to SERM treatment (Leung, 2007). All of this taken together shows
the importance of estrogen levels which may correlate to the rate of estrogen
dependent tumor progression, therefore the expression of estrogen’s potential target
genes may serve as good prognostic markers.
3

Estrogen is known to induce pS2 gene expression which produces a pS2 protein
(Horiguchi, 1996). In breast tumors the level of pS2 protein has become a potential
indicator for predicting treatability, relapse potential and survival (Foekens, 1990). pS2
may also be an indicator of early stage breast cancer, since it may not be expressed in
late stage breast cancer that have become independent of growth stimulation by
estrogen (Foekens, 1990). Although high levels of pS2 protein may indicate the
presence of proliferating breast cancer, it also indicates the presence of ER-α (Foekens,
1990). The presence of ER-α decreases the chance of relapse and increase survival due
to a fully functional estrogen receptor that is treatable (Foekens, 1990). ER-α positive
breast cancer may benefit from the ability to block growth progression by inhibiting the
estrogen receptor with selective estrogen receptor modulators (Park, 2002).
In ER+ breast cancer cells, not only are the levels of estrogen important, but also
the levels of testosterone are important due to aromatase activity in breast cancer
tissue that can convert androgen substrates into estrogen (Smith, 2003). Aromatase
therapy is used clinically to prevent the conversion of testosterone to estrogen, in
estrogen receptor positive breast cancers (Smith, 2003). Inhibiting aromatase activity in
breast cancer is beneficial in two ways, it results in decreased estrogen levels due to the
loss of testosterone conversion to estrogen, and testosterone may actually have a
protective effect on male and female breast cancer by inducing cell cycle arrest (Zhou,
2003, Dimitrakakis, 2003, and Lobaccaro, 1993). This protective cell cycle arrest by
testosterone could potentially come from the ability of testosterone bound androgen
receptors triggering increased p21 expression via an androgen response element
4

located 200 bp upstream of the p21 gene and proximal to the promoter region (Lu,
1999). However, testosterone regulation of other genes could play a significant role in
arresting a cell when treated with testosterone.
Prostate Cancer
Screening for prostate cancer often begins when men receive digital rectal exams as
part of a yearly physical to locate any irregularities in the back of the prostate. This
region of the prostate is where 85% of prostate cancers occur (Chodak, 1989). If
irregularities are found one of the next steps is screening for increased levels of a
specific serine protease, known as Prostate Specific Antigen (PSA), due to the
correlation of increased PSA levels with testosterone levels and positive prostate cancer
diagnosis (Thompsons, 2004). Increased levels of testosterone bound androgen
receptors will bind the known target gene PSA’s androgen response element located in
its promoter and signal increased gene expression (Thompsons, 2004). The potential for
positive diagnosis of high grade cancer with a Gleason score above seven (scale 0-10,
with 10 having worst prognosis) increased in men with PSA levels above 4.0 ng/mL of
blood serum, and significantly increased when PSA levels increased above 10.0 ng/mL of
blood serum (Thompsons, 2004). A concern with this test is that obese men tend to
have decreased PSA levels, which may lead to an increase in false negative results
(Fowke, 2006). Additionally there are other stresses such as long distance ambulation,
ejaculation and aggressive cycling which may lead to increased PSA levels at the time of
testing (Leibovitch, 2005). False diagnosis can potentially lead to unnecessary medical
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procedures, such as biopsy, or chemotherapy. Prostate cancer may also be associated
to low free serum testosterone levels and therefore PSA is not an accurate indicator of
potential prostate cancer (Morgenthaler, 1996). It was recently discovered that there
may not be an overall benefit to PSA screening. When comparing the survival rates of
prostate cancer patients who participated in PSA monitoring to those who did not have
PSA screenings there were no survival benefits (Andriole, 2012). A thirteen year study
recently concluded that the death rates per 10,000 patients were nearly that same (3.7
Vs. 3.4) when comparing a group undergoing scheduled PSA screening and digital rectal
exams to another group which did not undergo scheduled testing. It is possible that PSA
screening can false positively diagnose patients with high testosterone levels who do
not have prostate cancer but have PSA levels in the positive range, or patients can be
negatively diagnosed with androgen independent prostate cancer (Andriole, 2012).
Induction of Reactive Oxygen Species During Cellular Senescence.
In the mid 1960’s it was reported that in cell culture primary fibroblasts undergo
growth arrest after a finite number of cellular divisions resulting from the erosion of
telomeres (Hayflick, 1965). This finite number of divisions became known as Hayflick’s
limit (Hayflick, 1965). After Hayflick’s limit is reached cells enter an arrested state and
division ceases (Hayflick, 1965). This growth arrest was coined intrinsic replicative
senescence. As telomeres deteriorate the exposed chromosomal ends are sensed as
DNA damage and a DNA damage response occurs. The DNA damage response can be
activated by intrinsic factors such as telomere shortening, as well as extrinsic factors,
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such as culture conditions, UV or chemical damage. DNA damage activates ATM and
ATR, which lead to activation of p53 via phosphorylation by CHK1/CHK2 (Bennett, 2001).
Activation of p53 increases gene expression of p21 which leads to a transient G1 cell
cycle arrest and an increase in ROS levels (Passos, 2010). This increase in ROS maintains
growth arrest by causing additional DNA damage until the cell is permanently arrested
(Passos, 2010). If ROS levels are decreased during transient cell cycle arrest, a cell can
reenter the cell cycle and begin replication (Lu, 2009). Not all cellular senescence
mechanisms are dependent on DNA damage, but rather a third senescence pathway
exists.
Oncogene induced senescence is caused by mitogenic stimuli which can activate RAS
and lead to increased levels of ROS in both immortalized cells and human diploid
fibroblasts (Moiseeva, 2009). The mechanism by which RAS causes increased ROS
production is not fully understood, however via signaling through the
RAS/RAF/MEK/ERK signaling pathway, activation of ERK can disrupt the mitochondrial
membrane, signal cell cycle arrest through p21 and activate NADPH oxidase which
produces superoxide, a form of ROS (Cagnol, 2010 and Serrano, 1997). When p21 gene
expression increases it can also increase ROS production which inhibits phosphatases
that could inactivate RAS, RAF, MEK or ERK and allows continuous signaling to increase
p53 levels through ERK (Passos, 2010 and Serrano, 1997). Cells also trigger increased
p53 protein levels via RAF inactivation of AKT which causes dephosphorylation of Mdm2
and blocks Mdm2 mediated degradation of p53 (Cagnol, 2009). Oncogenic signaling
through such transcription factors as DMP1 can also activate ARF which blocks MDM2
7

and stabilizes p53, leading to an increase of p53 (Zindy, 1998). When the level of
reactive oxygen species overwhelms the natural antioxidant defenses an oxidative stress
response may occur causing mutations and damage to DNA, which induces a DNA
damage response (Campisi, 2007).
Common to replicative senescence, the DNA damage response pathway and
oncogene induced senescence is the activation of p53. p53 is one of the most important
tumor suppressors, and has been given the moniker “Guardian of the Genome” for its
ability to actively suppress cellular growth (Lane, 1992). p53 primarily functions as a
transcription factor that is kept inactive due to rapid degradation by Mdm2, however
various cellular stresses can block Mdm2 mediated degradation leading to p53
accumulation (Louria-Hayon, 2003). This accumulation causes p53 to activate cell cycle
inhibitors which induces apoptosis, cellular senescence, or a transient growth arrest that
can be reversed (Lowe, 2004 and Vousden, 2002). Common to all tumor formation is
inactivation of p53 (Itahana, 2001). When p53 is inactivated it cannot activate its target
genes and the ability to maintain controlled cellular growth is lost, which is a hallmark of
tumor progression (Itahana, 2001).
Determining the activity of p53 target genes can help explain the functions of p53,
however there are hundreds of p53 target genes and complex activation patterns that
are cell type and stress specific (Harms, 2004). Some of these gene products are
redundant indicating that not just one p53 target is the basis for p53 dependent
senescence (Harms, 2004). Some of the targets of p53 that have been linked to a
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senescent response include p21, Promyelocytic leukemia PML, Plasminogen Activator
Inhibitor 1, and DEC1 (Harms, 2004). Although all of these target proteins elicit cellular
senescence, their mechanisms are different, PML acts to stabilize p53 by inhibiting
degradation by Mdm2, Plasminogen Activator Inhibitor 1 can trigger replicative
senescence and DEC1 mediates p53 dependent G1 cell cycle arrest (Qian, 2010). This
signifies the importance of p53 activating many targets to induce growth arrest (Harms,
2004). PML, p21, PAI-1 and DEC1 lead to cellular senescence after activation by p53;
however in the absence of these targets p53 can still elicit a senescence response, which
indicates that there are other p53 targets that activate senescence and the importance
of discovering novel p53 targets that cause cellular senescence (Harms, 2004).
Recently the YPEL3 gene was reported to be directly activated by p53 and capable of
eliciting growth arrest in tumor cells (Kelley, 2010). Based on several assays it was
determined that YPEL3 induction triggers cellular senescence (Kelley, 2010). However,
YPEL3 is not only regulated by p53. It was recently discovered that in breast cancer cells
YPEL3 is repressed by estrogen signaling through estrogen receptor α (Tuttle, 2011).
Blocking estrogen signaling triggered p53 independent cellular senescence (Tuttle,
2011). The mechanism by which YPEL3 leads to cellular senescence is not readily
known. One goal of this thesis is to explore whether YPEL3 expression triggers ROS.
Yippee Like 3 (YPEL3)
Yippee was discovered in Drosophila via a yeast interaction trap that screened for
proteins with potential interactions to hemolin of Cecropia Moth, also known by its
9

Binomial nomenclature as Hyalophora cecropia (Roxstrom, 2001). Hemolin is a
constitutively active member of the IG superfamily that is expressed at increased levels
during development and bacterial infection (Roxstrom, 2001). Increased hemolin levels
serve an immunological function by binding to bacteria and lipopolysaccharides which
enhance phagocytosis and activate protein kinase C (Roxstrom, 2001). Further research
to determine the role of Yippee binding to hemolin has not been conducted (Roxstrom,
2001). Sequencing of subcloned fragments revealed that the Yippee gene has four
exons which encode a 121 amino acid protein harboring a conserved putative zinc
binding ring finger motif comprised of four cysteine residues (Roxstrom, 2001). An
EMBL database search located a human protein sequence, with 76% sequence
homology to the Drosophilia Yippee protein, which was later found to harbor the same
conserved zinc finger motifs found on the Drosophilia Yippee protein (Roxstrom, 2001
and Honoso, 2004). This human sequence was later determined to be a paralog of the
human YPEL family and subsequently named YPEL5 (Honoso, 2004).
While characterization of the Yippee gene ceased, comprehensive sequence analysis
of a 350 kb region of chromosome 22 revealed a Di Georges synteny region in mice
which contained a novel mouse gene associated with 22q deletion syndrome (Farlie,
2001). Deletion at the 22q chromosomal region in humans led to the development of
craniofacial abnormalities, specifically Di George syndrome, as well as cardiac
abnormalities and thymic hypoplasia (Scrambler, 2000 and Farlie, 2001). The novel
mouse gene, named YPEL1, was subject to a BLAST sequence analysis search and a
highly homologous human sequence was found (Farlie, 2001). This sequence was
10

determined to be a human homolog of the mouse YPEL1 gene, which had previously
been identified as a homolog of the Yippee gene in Drosophilia (Farlie, 2001 and
Honoso, 2004).
In 2003, it was announced that sequencing of the human genome had been
completed which allowed for sequence analysis of unknown genes or sequences against
the whole human genome. A blast search using the human YPEL1 sequence against the
entire human genome identified four additional human paralogs (Honoso, 2004). The
five human paralogs discovered were subsequently named YPEL1-5 after the Yippee like
gene found in Drosophilia and were found to have high sequence homology from slime
mold to humans (Honoso, 2004). Interestingly, using RT-PCR analysis it was discovered
that YPEL1, YPEL2 and YPEL4 display a restrictive pattern of expression in adult and fetal
tissue while YPEL3 and YPEL5 are found to be constitutively active in all tissues tested
(Honoso, 2004).
A potential function for YPEL3 was discovered when Murine Small Unstable Apoptotic
Protein (SUAP), which has detrimental effects on actively dividing cells, was determined
to be the mouse homolog of human YPEL3 (Kelley, 2010). Prior to making this
connection it was discovered that mouse YPEL3 gene has 100% sequence homology to
human YPEL3 indicating a potential orthologous gene (Hosono, 2004). SUAP (mouse
YPEL3) in murine myeloid precursor cells suppresses IL-3 dependent proliferation and its
overexpression induced apoptosis following IL-3 withdraw (Baker, 2003). The
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detrimental effect SUAP (mouse YPEL3) has on proliferating cells suggests human YPEL3
may play a role in blocking cell cycle progression.
Interest over the YPEL3 paralog increased due to microarray analysis linking YPEL3 as
a potential target of p53 (Heminger, 2009). Increasing the level of p53 by knockdown of
the p53 negative regulators HdmX and Hdm2 induced YPEL3 gene expression when
compared to cells with fully functional HdmX and Hdm2 (Heminger, 2009). The YPEL3
gene was found to be induced in a p53 dependent manner in the presence of DNA
damaging agents (Kelley, 2010). The activation of a cotransfected luciferase reporter
vector harboring three putative p53 half sites with a wild type p53 indicated that p53
can directly bind to the YPEL3 gene promoter when damage is induced (Kelley, 2010). A
chromatin immunoprecipitation assay further proved that p53 binds the YPEL3 gene
promoter in vivo (Kelley, 2010). Taken together, it was determinde that YPEL3 acts
downstream of p53 (Kelley, 2010).
Since YPEL3 gene expression is regulated by p53, and p53 is known to induce growth
arrest, potential functions of YPEL3 were examined. Increasing YPEL3 gene expression
in a p53 independent manner indicated growth suppression which was shown by
decreased levels of colonies in a colony formation assay and growth arrest indicated by
an increase in cells in the G1 or S phase (Kelley, 2010 and Berberich, 2011). Growth
arrest in cells overexpressing YPEL3 was determined to be cellular senescence; which
was confirmed by an increase in β-Galactosidase levels, a hallmark of cellular
senescence (Kelley, 2010). This indicates that human YPEL3 can cause cellular
senescence independent of p53 (Kelley, 2010). Although it was previously predicted
12

that YPEL3 may lead to apoptosis, as does mouse YPEL3, no increase in apoptotic cells
were seen when YPEL3 gene expression was increased (Kelley, 2010). However, it was
noted that both mouse and human YPEL3 are rapidly degraded by ubiquitin mediated
proteasomes (Baker, 2003 and Kelly Miller Personal Communication).

YPEL3 Is Inactivated In Human Cancers.
Due to growth suppressive effects of YPEL3 it was predicted that YPEL3 is
downregulated in human cancers since cancer exhibits unregulated growth progression.
As expected, in colon, lung and ovarian tumors YPEL3 was found to be downregulated,
hence suppressing its growth repressive mechanism (Kelley, 2010 and Tuttle, 2011).
Further analysis of various cell lines uncovered that YPEL3 downregulation can occur
epigentically through hypermethylation of a 950bp CpG island found near the promoter
and histone acetylation, as well as through a p53 independent pathway involving
estrogen signaling via estrogen receptor α (Kelley, 2010 and Tuttle, 2011). When
estrogen is bound to estrogen receptor α it elicits a suppressive effect on YPEL3 gene
expression (Tuttle, 2011). Estrogen receptor α is imperative to YPEL3 gene suppression
because following ER-α knockdown YPEL3 gene expression increases, even in the
presence of estrogen (Tuttle, 2011). However, upon the removal of estrogen in
estrogen receptor positive cells an increase in YPEL3 gene expression is also seen
indicating the importance of estrogen as well as its receptor in gene suppression. The
growth suppressive effects of an estrogen antagonist such as selective estrogen
receptor modulator Tamoxifen is able to induce YPEL3 gene expression (Tuttle, 2011).
13

The culmination of these findings, coupled with the growth promoting activities of
testosterone led us to explore YPEL3 gene expression regulation by testosterone in
breast and prostate cancer cells. It has also led to studies that examine the downstream
effects of YPEL3 that elicit senescence, given that the senescence pathway that is
activated upon activation of YPEL3 is not well understood. One potential mechanism
that was examined in this thesis was whether YPEL3 triggered an increase in intracellular
ROS.

Purpose
The purpose of this study is to further examine the effects of hormone regulation on
YPEL3 gene expression, determine if increased YPEL3 gene expression can cause ROS
production, and find potential proteins that interact with YPEL3. It has been previously
shown that increased YPEL3 levels induce cellular senescence; however this pathway is
not yet fully understood. In the first objective of this thesis, which is derived from
previous work revealing the ability of estrogen to suppress YPEL3 in breast cancer, the
effects of testosterone on LnCAP cells and MCF7 cells were examined. We have
previously seen that overexpressionof YPEL3 induces cellular senescence and wanted to
determine if this may have any correlation to Reactive Oxygen Species production. For
the second part of this thesis the hypothesis that YPEL3 expression leads to increased
ROS production was tested in IMR90 and MCF7 cells. The third part of this thesis will
present preliminary findings of potential proteins that interact with the YPEL3 protein.
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The results from this thesis may provide insight into new potential therapeutic targets
and get us closer to identifying the pathway by which YPEL3 induces cellular senescence.
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II. Materials and Methods
Cells and Reagents
LnCAP cells derived from a prostate adenocarcinoma were grown in RPMI 1640
media supplemented with 10% fetal bovine serum (FBS) and 10 μg/mL gentamycin.
MCF7 breast carcinoma cells and IMR90 primary human diploid fibroblasts (less than 20
passages) were grown in Dulbeco’s Modified Eagle Medium (DMEM) supplemented with
10% FBS and 10 μg/mL gentamycin (complete media). All cell lines were purchased
from American Type Culture Collection.
Reagents used to treat cells include doxocycline or tetracycline (Clontech), β-estradiol
(Sigma), and testosterone (Sigma).
Virus Infections
Lentivirus that had previously been produced were thawed and used to infect MCF7
cells, as well as IMR90 cells (Table 1). Cells were plated at a minimum density of 50K to
a maximum density of 200k in complete media. After 24 hours the complete media was
removed and a mixture containing viral supernatant (1 mL), complete media (1 mL) and
Polybrene (6 µg/mL) was added. The infected cells were incubated for 24 hours before
being refed with complete media. After an additional 24 hours antibiotic selection was
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Lentiviral Plasmid

Antibiotic

MCF7

IMR90

750

100

µg/mL

µg/mL

Resistance
pLenti4-YPEL3-V5

Zeocin

pLenti6-RAS

Blasticidin

6 µg/mL

5 µg/mL

pLenti6-GFP

Blasticidin

6 µg/mL

5 µg/mL

Table 1: Lentiviral Plasmid and Antibiotic Doses for MCF7 and IMR90 cell lines.
Lowest dose of selecting agent needed to eradicate cells not expressing a resistance
gene. Blasticidin and Zeocin were obtained from Invitrogen. (Experiments conducted
by Kate Heminger)
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added and selection continued until no viable cells were left in a parallel mock infected
plate (Table 1). The lowest dose of Zeocin or Blasticidin used for antibiotic selection had
previously been determined by kill curve experiments in MCF7 and IMR90 cells (Table
1). Antibiotic selection exposure ranged from 7 to 12 days, after which cells were refed
with complete media for 24 to 72 hours.
Generating and Detecting Intracellular Reactive Oxygen Species
IMR90 and MCF7 cells were plated at a density of 200k cells per well in a six well or 6
cm culture plate. To elicit reactive oxygen species (ROS) activity, after 24 hours cells
were treated with 10 μM of Hydrogen Peroxide (Cumberland Swan Inc) in DMEM + FBS
for 2 hours. Media was removed and adherent cells were rinsed with Dulbeco’s
Phosphate Buffered Saline (DPBS). DPBS was removed and 1mL of DPBS was added to
each well along with 8 μM of DCFDA (D399 H2DCFDA and C6827 CM-H2DCFDA
Invitrogen) reconstituted in Dimethyl Sulfoxide (DMSO). After preliminary studies a
switch from H2DCFDA to CM-H2DCFDA was made due to availability, but this was
beneficial due to better retention in live cells. The dye (H2DCFDA or CM-H2DCFDA) was
added to six well or 6 cm culture plates. Cells were incubated at 37oC for 30 minutes
wrapped in aluminum foil to avoid light induced oxidation. Adherent cells in 6 well or 6
cm culture plates were rinsed with DPBS, scraped and resuspended in DPBS in 5 mL snap
cap tubes for flow cytommetry.
Cells undergoing flow cytommetry analysis were scraped in DPBS into 5 mL snap cap
tubes and wrapped in aluminum foil to deter light induced oxidation. Flow cytommetry
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was performed on a BD Accuri C6 Personal Flow Cytometer with a run limit of 30,000
events and using the preset medium fluidics setting of 35 µL per minute and a core size
setting of 16 µm. Results were analyzed using CF-20 CFlow Plus Analysis Software and
FCS Express version 3 or 4(De Novo Software). Histogram plots were analyzed in log
scale on the X-axis by setting it to FL1-A and linear scale on the Y-axis by setting to cell
count.
RNA Isolation
Cells were rinsed 1 time with Dulbecco's Phosphate Buffered Saline (DPBS) and then
lysed with TRK lysis buffer supplemented with 2% β-mercaptoethanol. The lysate was
transferred to an Eppendorf tube and frozen at -80oC until needed. After thawing, 1
volume of 70% ethanol was added to each sample followed by vortexing. RNA was
isolated following the e.Z.N.A. Total RNA kit (Omega Bio-Tek) protocol. RNA was eluted
in 40μL of DEPC water that had been heated to 70oC and incubated on the spin column
pad for 5 minutes. RNA quantification was performed on a NanoDrop DN-1000
spectrophotometer with RNA purity being determined by the absorbance ratio at 260
nm and 280 nm. A ratio of 1.8-2.1 signified good quality RNA.
Reverse Transcription
CDNA was created by mixing 500 ng of RNA, 4 μL of qScript cDNA supermix (Quanta
Biosciences Inc.) and enough sterile distilled water to bring the reaction to a total of 20
µL. The reaction was incubated for 5 minutes at 25oC, 30 minutes at 42oC , 5 minutes at
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85oC followed by indefinite holding at 4oC (ABI 2700). The cDNA was then diluted with
200 µL of sterile distilled water prior to quantitative PCR.
Taqman Base PCR
The ABI 7900HT sequence detection system (Applied Biosystems) was used to
perform quantitative real time PCR in quadruplicate on a 96 well microtiter plate. The
20 μL Taqman based PCR reaction was prepared by combining 9 μL of the diluted cDNA
mix with a 11 μL master mix containing 10 μL of 2X Taqman Universal PCR master mix
(Applied Biosystems) and 1 μL of the appropriate 20x Taqman Assay-on-Demand Gene
Expression product (Applied Biosystems). The reactions were then subjected to 2
minutes at 50°C, 10 minutes at 95°C followed by 40 cycles of 15 seconds at 95°C and 1
minute at 60°C. Target gene expression was normalized to GAPDH expression and
analysis of gene expression was performed using SDS 2.2.2 software (ABI) setting a
confidence interval of 95%. Outlier Ct values were assessed based on the ΔCtSD values.
Outliers were automatically and manually removed to improve the RQ minimum and
maximum range.
Protein Extraction
Cells were rinsed with 5 mL of DPBS and harvested by scraping into 5 mL of fresh
DPBS. Cellular suspensions of five 15 cm plates were combined into a 50 mL test tube
and pelleted by centrifugation at 4000 RPM for 2 minutes. The supernatant was
carefully drawn off the pellet. Pellets were stored at -80oC until needed. Based on the
cell pellet size, five volumes of lysis buffer (50 mM Tris pH 8.0, 5mM EDTA, 150nM NaCl,
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0.5% Nonident p-40, 1mM phenylmethanesulfonylfluoride (Sigma), 1mM Dithiothreitol
(Sigma) and Protease Inhibitor Coctail (Sigma)) were added and the frozen pellet was
allowed to thaw on ice. The pellet was gently resuspended and transferred to a new 50
mL screw cap tube for centrifugation in a 4oC environment at 11,000 RPM (15,000G) for
15 minutes. The soluble protein fraction was transferred from the insoluble material to
a clean 15mL test tube. A Bradford Protein Assay was used to determine the protein
concentration of the cell extract. Bovine Serum Albumin acetylated (BSA) (Promega)
was used to generate a standard curve at by adding 2 μg, 5 μg or 10 μg to 800 μL of
sterile distilled water (SDW) and 200μL of Bradford Protein Assay Dye Reagent (BioRad). Unknown protein concentrations were determined by adding 5 μL of protein that
had been diluted tenfold to 800 μL of SDW and 200 μL of Bradford Protein Assay Dye
Reagent. The samples and standards were transferred to plastic cuvettes and
absorbance was measured at 595nM on either a Genesys 5 Spectrophotometer or
Genesys 6 Spectrophotometer (Thermospectronic). The protein samples concentrations
were determined by comparing their absorbencies to the standard BSA absorbencies.
Co-Immunoprecipitation
A total of 100 mg of protein obtained by the protein extraction method was moved
to a new test tube diluted to 10 mL with lysis buffer. To each reaction either 40 μg (80
μL) of Agarose Immobilized Rabbit Anti V5 beads (Bethyl), or 80 μL Anti V5 Agarose Gel
produced in mouse (Sigma) was added and allowed to incubate overnight at 4oC. Each
sample was centrifuged at 4000 rpm for 8 minutes at 4oC. Lysis buffer was removed by
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pipetting and resuspended in 6 mL of fresh lysis byffer followed by incubation for 5
minutes at 4oC on a rotating platform. This washing process was repeated 6 times and a
fraction (F#) of each wash was saved. Following the washes, the beads were transferred
to a 1.5 mL Eppendorf test tube by adding 1 mL of lysis buffer to the beads and
resuspending. The beads were centrifuged in a 4oC microfuge at 10,000 rpm for 5
minutes and excess lysis buffer was removed from the bead pellet. At this point the
bound proteins were either eluted by adding 50 μL of 1X SDS Page Running Buffer to the
beads and heating for 5 minutes at 37oC, or 0.8 mg (200 μL) of competing V5 peptide
(Sigma) added to the beads, inverted at 4oC for 5 minutes, 4oC cold centrifuged for 5
minutes at 10,000 rpm and repeated to obtain 2 eluted fractions (EF#). When samples
were eluted with V5 peptide after the second elution the beads were resuspended in 50
μL of 2X SDS Dye and heated to 70oC for 5 minutes. The beads were centrifuged in a 4oC
microfuge at 10,000 rpm for 5 minutes and the bead fraction was removed from the
bead pellet. The 2 eluted fractions (EF) from each cell set were combined and
concentrated by adding 3.6 mL of lysis buffer to the elutions and loading into an Amicon
Ultra Centrifugal Filter 3k molecular weight ultracell (Millipore) which was centrifuged at
3600 g for 70 minutes at 4oC. Alternatively, the EF was concentrated by loading each
fraction into a Microcon Ultracel YM-10 centrifugal filter (Sigma) which was centrifuged
at 10,000 RPM for 10 minutes at 4oC. For both concentration methods the flow through
was removed and additional lysis buffer was added to desalt the proteins. The proteins
were concentrated in a volume of 20 µL of Lysis buffer. To the retentate, 20 µL of lysis
buffer was added and vigorous pipetting was used to loosen proteins from the
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membrane. The retentate was combined with an equal amount of 2X SDS loading Dye
and stored at -80oC until further use.
SDS-PAGE Electrophoresis
Protein extracts were combined with an equal volume of 2X SDS loading dye (1X = 60
mM Tris, pH7.6, 2% SDS, 10% glycerol) and loaded into either a large 12% SDS-Page gel
with a 4% stacking gel run in a V16 electrophoresis apparatus (Gibco Bethesda Research
Laboratories) with 1X SDS running buffer (25 mM Tris pH 8.3, 250 mM glycine, 0.1% SDS)
at 150V for approximately 30 minutes then 250V for approximately 1.5 hours , or a
precast 8-16% Precise Protein Tris Hepes Gradient Gel (Thermo Scientific) run in BupH
Tris Hepes SDS running buffer (Thermo Scientific), reconstituted in deionized water, for
approximately 45 minutes at 150V using an Owl P8D (Owl Separation Systems Inc).
Western Blot
Denatured proteins were transferred from the SDS-PAGE gel to polyvinylidene
difluoride (PVDF) membrane (Millipore), that had been presoaked in 100% methanol for
15 seconds and then transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH
8.3) for 5 minutes, via a Bio-Rad Mini Protean 2 transfer system for 1 hour at .5 Amps in
transfer buffer. After transfer the PVDF membrane was dried and then placed in PBS
blocking buffer (1X PBS, 5% non-fat dry milk (NFDM), 0.1% Tween-20) for 24 hours on a
moving platform at 4oC. Primary antibody (monoclonal V5) (Sigma) was added at a
concentration from 1:1000-1:5000 in diluted PBS blocking buffer (1:10) for a minimum
of 5 hours (Room Temperature) and a maximum of 24 hours (4 oC). The PVDF
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membrane was washed 5 times for 15 minutes each in diluted PBS blocking buffer. The
secondary antibody with conjugated horseradish peroxidase enzyme (Goat Anti Mouse)
(Promega) was added at a concentration of 1:2500 in diluted PBS blocking buffer and
allowed to incubate for 1 hour at room temperature. The PVDF membrane was again
washed 5 times for 15 minutes each in diluted PBS blocking buffer and exposed to Super
Signal West Pico Chemiluminesence (Thermo Scientific) for 2-3 minutes.
Chemiluminescent images of the blot were taken in a FUJI FILM LAS 4000 image reader
and the images were were visualized using Fujifilm Multi Guage software. To reprobe
the PVDF membrane, it was first stripped with two 30 minute treatments in Western
Strip Buffer (25 mM glycine, 1% SDS, pH 2.0). The membrane was rinsed extensively in
DPBS and then reblocked with DPBS blocking buffer before repeating the above
protocol.
Colloidal Blue and Silver Staining
SDS-Page protein gels were fixed in 40% methanol and 5% acetic acid overnight on a
shaker. Gels were then stained following the NuPage Bis Tris protocol contained in the
Novex Colloidal Blue Stain kit (Invitrogen). To silver stain a gel it was first fixed in 40%
ethanol and then one of the following three methods were employed. The first method
was to follow the protocol from the Bio-Rad Silver stain kit (Bio-Rad). The second
method exposed the gel 2 times to 10% glutaraldehyde for 3 minutes each. The gel was
then placed in 200 nM Dithiothreitol for 10 minutes, followed by .1% silver nitrate for 15
minutes. The gel was rinsed 2 times with sterile distilled water (SDW) for 1 minute each

24

to remove excess silver nitrate. Formalin (0.4%) plus 2% sodium carbonate was used to
develop the gel with an exposure time between 4 to 8 minutes. Development of the gel
was stopped by placing it in 1% acetic acid. The third method fixed the gel in 20mg/mL
sodium thiosulfate for 2 minutes. The gel was then rinsed in SDW twice for one minute
each. After rinsing, the gel was exposed to .1% silver nitrate for 30 minutes. The excess
silver nitrate was then removed by washing twice with SDW for 1 minute each. The gel
was developed with .04% formalin plus 2% sodium carbonate with an exposure time
between 4 to 8 minutes. Acetic acid (1%) was used to stop development of the gel
indefinitely.
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III. Hormone Regulation of YPEL3
The effects of testosterone on YPEL3 Expression in LnCAPs
It has previously been shown in estrogen receptor positive MCF7 breast cancer cells
that growth in the presence of estrogen leads to a repression of YPEL3 gene expression
(Tuttle 2011). In addition to estrogen receptors, MCF7 cells also harbor androgen
receptors (Ortmann, 2002). However, the effects of testosterone on YPEL3 gene
expression are unknown in MCF7 cells. Also unknown are the effects that steroid
hormones play on YPEL3 gene expression in non breast cancer cell lines. Steroid
hormones, which include estrogen, progesterone and testosterone, diffuse into cells
where they bind their respective cytoplasmic receptor and are translocated into the
nucleus to impart growth stimulation or inhibition. LnCAP cells, which are derived from
human prostate adenocarcinoma, are a hormonally responsive cell line containing both
androgen and estrogen receptors (Horoszewicz, 1983). The presence of estrogen or
testosterone has been shown to have growth stimulating effects on LnCAPs
(Castagnetta, 1995 and Kampa, 2002)
To determine whether hormones regulate YPEL3 gene expression in prostate cancer
cells, LnCAP cells were grown in complete media or charcoal stripped serum (CSS) for up
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Figure 1: YPEL3 Expression Is Induced In LnCAP Cells Grown In CSS.
LnCAP cells were plated in complete media for 24 hours before being switched to
CSS, or refed with complete media. RNA from cells grown in complete media was
isolated 24 hours after the first feeding (CM). Cells grown in charcoal stripped serum
were either fed every 24 hours (CSS *), or the media remained unchanged (CSS). RNA
was isolated after 24, 48 and 72 hours. YPEL3 mRNA levels were analyzed using RT-PCR
normalized to GAPDH mRNA levels. Error bars represent the 95% confidence intervals
resulting from triplicate assays for both YPEL3 and GAPDH expression.
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to a total of 72 hours (Figure 1). Growing cells in CSS, which is devoid of all hormones as
well as other lipophilic compounds including certain growth factors and cytokines, gives
the ability to analyze the impact of hormone removal on YPEL3 gene expression. LnCAP
cells were grown in complete media or CSS media for 24, 48 or 72 hours prior to total
RNA isolation and RT-PCR analysis for YPEL3 mRNA levels. YPEL3 gene expression
increased 2 fold in the LnCAP cells cultured in CSS after 24 hours and continued to
increase up to 4.7 fold at 72 hours when fed every 24 hours. Regardless of feeding
schedules if the LnCAP cells were fed fresh CSS media every 24 hours or not there is an
induction of YPEL3 gene expression caused by culturing LnCAP cells in CSS media, when
compared to complete media.
Having demonstrated that growing LnCAP cells in CSS media induces YPEL3
expression the next series of experiments tested the effect of administering
testosterone on YPEL3 gene expression. Testosterone is an important regulator of cell
cycle progression and proliferation in LnCAP cells, however it is unknown if testosterone
plays a role in regulating YPEL3 gene expression. By performing a dose response the
effects of various testosterone doses on YPEL3 gene expression was determined. LnCAP
cells were initially grown in complete media for 24 hours then switched to CSS and
varying doses of testosterone (0-100 nM) were administered to the CSS media (Figure
2). RNA was isolated 24 hours post testosterone treatments and mRNA levels of PSA
and YPEL3 were assessed by RT-PCR. PSA was used as a positive control since its
induction by testosterone in LnCAP cells has been previously reported (Kampa, 2002).
As expected the addition of testosterone resulted in a dose-dependent induction of
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Figure 2: YPEL3 is repressed in LnCAP cells in the presence of Testosterone.
LnCAP cells were grown in complete media for 24 hours before being switched to
charcoal stripped serum. After 24 hours testosterone was added at doses of 2, 5, 10,
25, and 100 nM to the CSS media. RNA was isolated 24 hours after testosterone
exposure. (B) YPEL3 and (A) PSA mRNA levels were analyzed using RT-PCR normalized
to GAPDH mRNA levels. Error bars represent the 95% confidence intervals resulting
from triplicate assays for PSA, YPEL3 and GAPDH expression.
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PSA gene expression (Figure 2A). In contrast, YPEL3 showed a consistent 80% reduction
in gene expression across the range of testosterone treatments (Figure 2B). These
results suggest that YPEL3 expression is repressed by testosterone in LnCAP cells.
Prostate cells normally do not possess aromatase activity which converts androgens
to estrogen, however upon conversion to a malignant state; LnCAP prostate cells begin
to express aromatase (Ellem, 2004). By monitoring the expression of pS2, which is a
target gene of estrogen, we could indirectly assess whether testosterone was being
converted to estrogen in LnCAP cells. LnCAPs were grown in CSS to induce YPEL3 and a
testosterone time course using 10 nM was set up (Figure 3). A dose of 10 nM was
chosen because not only was it shown in the dose response from Figure 2 to give the
largest repression of YPEL3 gene expression and the second highest PSA induction, but
also because aromatase activity in LnCAP cells has been shown to not exceed a
conversion rate of .54 nM of testosterone to estrogen over 72 hours (Castagnetta,
1997). By saturating the aromatase enzymes it can be determined if testosterone has
an impact on YPEL3 gene expression, or if its conversion to estrogen potentially
regulates YPEL3 gene expression. Higher doses of testosterone may give a marginally
higher PSA induction that is not statistically different from 10 nM, but higher doses do
not repress YPEL3 gene expression as well. Isolating total RNA at hourly time points of
2, 4, 8, 24, and 48 hours followed by quantification of mRNA levels for YPEL3 and PSA by
RT-PCR analysis, was used to generate a time course curve to determine PSA and YPEL3
gene expression levels. Analysis of PSA gene expression by time course curve revealed
that MCF7 cells grown in the presence of 10 nM testosterone induced PSA gene
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Figure 3: YPEL3 Repression is inversely related to PSA expression in LnCAP Cells
exposed to 10 nM Testosterone for 48 hours. LnCAP cells were plated in complete
media for 24 hours before being switched to CSS. After 24 hours 10 nM testosterone
was added to the CSS media. RNA was isolated at 2, 4, 8, 24 and 48 hour timepoints.
YPEL3, PSA and PS2 mRNA levels were analyzed using RT-PCR normalized to GAPDH
mRNA levels. Error bars represent the 95% confidence intervals resulting from triplicate
assays for PSA, YPEL3, PS2 and GAPDH expression.
*Outlying data at 8 hours was removed for YPEL3.
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expression increases up to 24 hours before PSA gene expression began to return to
baseline levels. Alternatively, testosterone (10 nM) caused maximal repression of YPEL3
gene expression at 24 hours and continued maximal repression at 48 hours. At 24 hours
there was a 12 fold increase in PSA, which was the highest, and also a 38% reduction in
YPEL3, which was the largest reduction. However, at 48 hours there was a 4 fold
induction of PSA, which may be attributed to testosterone degradation (t½= 2-4 Hr) as
well as the turnover and synthesis rate of androgen receptors (Eckert, 1984). Levels of
pS2 mRNA were also quantified by RT-PCR, revealing no change in pS2 gene expression
in LnCAPs over 48 hours, suggesting that testosterone is not being converted to
estrogen under these conditions.
Testosterone replacement therapy can have beneficial effects when administered in
the event of Hypogonadism, or low testosterone levels. However, if an androgen
receptor positive prostate cancer is present testosterone may lead to a more aggressive
cancer.
After a prostatectomy, which removes the prostate, testosterone replacement
therapy is used to maintain lost testosterone production; however testosterone may
also induce growth progression of metastatic prostate cancer cells that have evaded
prostatectomy and chemotherapeutic treatment. The addition of testosterone to
LnCAP prostate cells has a repressive effect on YPEL3 gene expression which may lead to
cell cycle progression. This strengthens the idea that testosterone replacement therapy
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is not the best choice when androgen responsive prostate cancer is suspected, due to its
ability to repress expression of YPEL3.
The effects of Testosterone on YPEL3 Expression in MCF7 Cells
The progression of estrogen receptor positive breast cancer has been linked to
estrogen induced cell proliferation (Katzenellenbogen, 1987). Testosterone on the
other hand has been shown to inhibit growth in androgen receptor positive breast
cancer cells (Ortmann, 2002). Cells that harbor both the androgen and estrogen
receptor like MCF-7 cells may proliferate in the presence of estrogen but proliferation is
inhibited in the presence of testosterone (Ortmann, 2002). The level of inhibition by
testosterone is slightly less in cells with aromatase activity due to its ability to convert
testosterone to estrogen (Ortmann, 2002). However, unlike LnCAP cells aromatase
expression is repressed at the transcriptional level in MCF7 breast cancer cells
(Castagnetta, 1997 and Zhou, 1993).
With the knowledge that YPEL3 is repressed in MCF7 cells in the presence of estrogen
we set forth to determine how testosterone impacted YPEL3 expression in MCF7 cells
when given alone or in combination with estrogen. MCF7 cells were utilized since they
contain estrogen and androgen receptors (Horwitz, 1975). MCF7 cells grown in CSS
were exposed to 1nM estrogen, 5nM testosterone, or a combination of both (Figure 4).
Estrogen was chosen at a dose of 1 nM due to previous research that shows no further
repression of YPEL3 in MCF7 breast cancer cells at higher doses (Tuttle, 2011). A dose of
5 nM testosterone was chosen because it was found to be near, or slightly more than
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Figure 4: Testosterone Induction and β-estradiol Repression of YPEL3 in MCF7 Cells.
MCF7 cells were plated in complete media for 24 hours before being switched to CSS.
The media was changed to CSS with the addition of either 1 nM Estrogen, 5 nM
testosterone, or a combination of Estrogen (1 nM) and testosterone (5 nM). RNA was
isolated after 24 hours. YPEL3 mRNA levels were analyzed using RT-PCR normalized to
GAPDH mRNA levels. Error bars represent the 95% confidence intervals resulting from
triplicate assays for both YPEL3 and GAPDH expression.
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the threshold of high to normal testosterone production (Schroder, 1998). As
expected, MCF7 cells treated for 24 hours with 1 nM of estrogen showed a 25%
repression of YPEL3 gene expression (Figure 4). MCF7 cells exposed to 5nM of
testosterone resulted in a 5.9 fold increase in YPEL3 mRNA levels, when compared to
CSS control, which is opposite of what was observed in LnCAP cells. Treatment with
both estrogen (1 nM) and testosterone (5 nM) showed a slight increase in YPEL3 gene
expression when compared to CSS control, suggesting that the two steroids have
opposing effects on YPEL3 mRNA expression.
To expand on the results obtained in Figure 4 comparing testosterone and estrogen
combination in MCF7 cells, a dose response curve with 1 nM estrogen and various doses
of testosterone was performed. By growing MCF7 cells in CSS media and adding various
doses of testosterone in addition to 1nM estrogen a dose response can be generated.
MCF7 cells were grown in CSS media for 24 hours before the addition of testosterone
(0.5 -10 nM) combined with 1 nM estrogen (Figure 5). Total mRNA was isolated after 24
hours, and as expected the CSS sample showed a near 2 fold induction of YPEL3 gene
expression. The addition of 0.5 nM testosterone and 1 nM estrogen represses YPEL3
gene expression back to levels that are statistically the same as MCF7 cells grown in
complete media. When testosterone and estrogen are administered both at 1 nM there
is an increase in YPEL3 gene expression relative to MCF7 cells grown in complete media,
but there is no statistical difference when compared to MCF7 cells grown in CSS.
However, YPEL3 gene expression increases in a dose dependant manner as testosterone
levels are increased above 1 nM. A combination of 5 nM testosterone and 1 nM
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Figure 5: In MCF7 Cells YPEL3 is Induced in the Presence of Increasing Doses of
Testosterone. MCF7 cells were plated in complete media for 24 hours before being
switched to CSS. After 24 hours of growth in CSS media MCF7 cells were exposed to 1
nM estrogen combined with either 0.5 nM, 1 nM, 5 nM, or 10 nM of testosterone. RNA
was isolated after 24 hours. YPEL3 levels were analyzed using RT-PCR normalized to
GAPDH mRNA levels. Error bars represent the 95% confidence intervals resulting from
triplicate assays for both YPEL3 and GAPDH expression.
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estrogen yielded a 3 fold increase in YPEL3 gene expression when compared to
complete media, and the first statistically significant increase when compared to MCF7
cells grown in CSS media. A further increase in YPEL3 gene expression to 4 fold was
seen when 10 nM testosterone was combined with 1nM estrogen. This indicates there
may be a counteracting effect between testosterone and estrogen.
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IV. Reactive Oxygen Species is not produced during YPEL3 induction.
Cellular senescence is the irreversible loss of cellular division which can be mediated
by an increase in the level of reactive oxygen species (ROS) (Passos, 2010). A cell
normally produces ROS as a byproduct of cellular respiration; however it has
mechanisms to convert potentially damaging reactive oxygen species to more stable
forms leading to minimal DNA damage (Nohl, 2004). A cell may regulate its ROS levels
by many different mechanisms, some are known, and others are novel mechanisms
being discovered. Recently our laboratory discovered that YPEL3 could trigger cellular
senescence when over expressed, however the mechanism leading to this senescence is
currently unknown (Kelley, 2010).
By adding hydrogen peroxide and cell permeable fluorescent indicator DCFDA, a cell
population positive for increased ROS can be segregated from a negative population.
When DCFDA enters a cell its acetate groups are cleaved by intracellular esterases to
DCF and oxidation by hydrogen peroxide causes DCF to emit fluorescencent
wavelengths after excitation. Fluorescence is due to an increase in the number of pi
orbital electrons that can be excited, conversion of DCFDA to a planar molecule and
disruption of conjugate electrons. DCF has an excitation absorbance at 490 nm,
therefore when exposed to an Accuri c6 flow cytometer’s 488 nm laser an excitation
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emission occurs at 527 nm which is detected by the FL1 optical filter that has a
maximum emission detection peak at 533 nm and a high or low detection range
spanning +/-15 nm from 533 nm. An increase in positive ROS producing cells will be
indicated by a shift to the right in the fluorescent peak on a histogram caused by
excitation of DCF electrons emitting a longer wavelength of energy than cells producing
a lower amount of ROS or not emitting a fluorescent signal. A shift to the right indicates
a higher level of fluorescence in a cell. To establish the peak fluorescence of DCFDA
treated cells I compared DCFDA treated MCF7 or IMR90 cells with a second population
of MCF7 or IMR90 cells treated with DCFDA and hydrogen peroxide. The shift in
population of hydrogen peroxide treated cells when compared to dye only cells allowed
me to determine the fluorescence threshold for positive and negative ROS producing
cells (Figure 6C and 6D, 8% untreated Vs. 19% H2O2).
To assess the best method to treat cells with DCFDA to optimize detection of ROS
positive cells two different approaches of DCFDA treatment were tested. In the first
experiment, MCF7 cells were preloaded with DCFDA and then exposed to hydrogen
peroxide for 2 hours (Figure 6A and 6B). The second experiment involved treating MCF7
cells with Hydrogen peroxide for 2 hours, then loading the cells with DCFDA for 30
minutes (Figure 6C and 6D). Following these treatments both sets of cells were rinsed
with DPBS and then scraped into DPBS for flow cytometry analysis. From the flow
cytometry results it appears that cells loaded with DCFDA for 30 minutes after hydrogen
peroxide exposure produced a slightly higher number of ROS positive cells than when
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Figure 6: Hydrogen Peroxide produces cellular reactive oxygen species levels
detectable with DCFDA. MCF7 cells were plated in complete media 24 hours prior to
treatment. (A and B) Preloaded with DCFDA (10 μM), followed by treatment of (B) with
H2O2 (10 μM) for 2 hours. (C) Treated with H2O2 (10 μM) for 2 hours, followed by 30
minute DCFDA (10 μM) exposure to (C and D). Cells were scraped in 1 mL DPBS and
resuspended into a single cell population before flow cytommetry analysis on an Accuri
C6 was performed. (A, B, C and D) Histograms that represent negative and positive ROS
producing populations. X-axis represent fluorescence (log scale) and Y-axis represents
cell count (linear scale).
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preloaded with DCFDA for 30 minutes and subsequently exposed to hydrogen peroxide
treatment. Pre or post treatment of DCFDA had no effect on the percentage of ROS
positive cells in the untreated samples (8%; Figures 6A and 6C). Although both methods
of DCFDA treatment detected an increase in ROS positive cells, all subsequent
experiments were performed using the DCFDA post-treatment approach.
Through hydrodynamic focusing the flow cytometer passes individual particles or
cells through the interrogation point containing a laser that determines cell size through
light scattering or excites fluorophores that emit a fluorescent signal. If cell damage or
cell clumping occurs while harvesting the cells it could lead to inaccurate readings
caused by debris or doublets. Although debris and doublets can be removed through
gating this may result in an inaccurate representation of the total population. To
determine optimized cell harvesting conditions two methods were tested. In the first
approach cells were scraped in DPBS and the cells were vortexed to create a single cell
population. Alternatively cells were trypsinized using 1 mL of trypsin. Trypsinized cells
were transferred to complete media to inactivate the trypsin, pelleted by centrifugation
and resuspended in DPBS. Comparison of the dot plots (Figure 7A) shows that the
trypsinized cells have a population with a high level of forward and side scatter that is
absent in the dot plot of the cells scraped in DPBS. The trypsinized cells have three
distinct peaks in their histogram compared to one in the DBPS scraped cells (Figure 7B).
To determine if cell doublets are forming a histogram comparing cell count and side
scatter pulse width was utilized. As individual cells pass through the fluidics system the
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Figure 7: MCF7 cells scraped in DPBS provides a better mechanism to isolate MCF7
cells for vehicle for analyis by flow cytommetry.
MCF7 cells were plated at 200k/per well in complete media 24 hours prior to treatment.
MCF7 cells were treated with DCFDA in DPBS for 30 minutes and scraped in DPBS (Row
1). Trypsinized cells were suspended in DMEM + 10% fbs before pelleting and
resuspending in DPBS (Row 2). Analysis was performed on an Accuri C6 flow cytometer
after samples were vortexed. (A) Dot plot analyzing forward scatter and side scatter. (B)
Histogram representation of FL1-A and cell count. (C) Histogram representation of side
scatter pulse width and cell count. (D) Histogram representation of gated single cell
population (0-100 w) from (C).

43

laser will determine their size using three different pulse parameters which includes
height, area and width. Cells moving through the flow cytometer encounter the laser
one at a time. When a doublet is encountered it is passed through the fluidics system
with the doublets orientation parallel to the fluidics system and perpendicular to the
laser. The doublets orientation will cause formation of a second peak that will appear
on the side scatter width and cell count histogram (Figure 7C). The first peak to the left
corresponds to single cells and the second peak, which has a higher fluorescence and
different light scatter will occur to the right on the histogram. The scraped cells do not
have a second peak in the side scatter width histogram and the majority of the cells are
present as single cell events (Figure 7C). Trypsinized cells form a second peak indicating
doublets, with more than two thirds of the cell population forming doublets (Figure 7C).
By gating out the doublets and reanalyzing (Figure 7D), histogram analysis shows that
there is a higher level of ROS production when cells are trypsinized, indicating
trypsinization may induce ROS production. This revealed that cells isolated by scraping
into DPBS gave interpretable results, whereas the trypsinized cells gave a false ROS
positive and exhibited clumping or the formation of doublets. By gating out the
doublets the trypsinized cells also gave a less accurate interpretation of the data
because less than a third of the population was represented, whereas the scraped cells
single cell population represents over 90% of the cells. Moving forward the method of
cell isolation was rinsing cells with DPBS after DCFDA treatments and scraping in 1 mL of
DPBS into 5 mL snap cap tubes, followed by vortexing to create a single cell population
before flow cytometry analysis.
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According to Invitrogen, as well as recent literature, reseeding cells in full serum
media for a short recovery period after DCFDA exposure gives cellular esterases time to
cleave acetate groups on the DCFDA molecules and for oxidation of DCF by ROS to cause
fluorescence (Eruslanov, 2010). Employing serum free media, in addition to full serum
media, allowed us to determine if increases in fluorescence are due to growth factors
stimulating metabolism, or esterasSes present in serum. To assess ROS levels after a
period of recovery MCF7 cells were treated with hydrogen peroxide (2 hours) followed
by DCFDA exposure (30 min) and were allowed to recover in full serum media (Figure
8A) or serum free media (Figure 8B) for 0, 30 minutes, 1 hour and 2 hours before
scraping into 1 mL DPBS for flow cytometry analysis.
Cells grown in full serum media (Figure 8A) were switched to DPBS while adding
DCFDA because according to Invitrogen the high level of primary and secondary amines
in full serum media can hydrolyze DCFDA to its active form which changes its charge and
impedes its entry into the cell. MCF7 cells grown in serum free media (SFM) remained
in SFM upon addition of hydrogen peroxide or DCFDA. Counter to the literature, the
level of ROS positive DCFDA fluorescence declines in MCF7 cells as the cells recover in
full serum media (Figures 8A and 8C). From the flow cytometry results it appears that
cells grown in full serum media and exposed to DCFDA for 30 minutes after hydrogen
peroxide exposure and no recovery period produced a larger number of ROS positive
cells than when grown in SFM and exposed to the same treatment (Figures 8A and 8B).
MCF7 cells recovering in full serum media or SFM after treatment with hydrogen
peroxide and DCFDA exhibit the same trend of ROS positive cells with the highest
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Figure 8: Allowing DCFDA treated MCF7 cells to recover in complete media after DCFDA
exposure does not lead to improved ROS positive detection. MCF7 cells were cultured in full
serum media over night. (A) MCF7 cells were treated with H2O2 (10 μM), followed by 30
minute exposure to DCFDA (10 μM) in DPBS. The negative control (DCFDA loaded in PBS) was
only exposed to DCFDA. Following treatment cells were washed with DPBS and fed with full
serum media. Cells were isolated at time points of 0, 30 minutes, 1 hour and 2 hours. (B) MCF7
cells were treated with H2O2 (10 μM), followed by 30 minute exposure to DCFDA (10 μM) in
serum free media. The negative control (MCF7 DCFDA loaded in SFM) was only exposed to
DCFDA. Following treatment cells were fed with serum free media. Cells were isolated at time
points of 0, 30 minutes, 1 hour and 2 hours by scraping in 1 mL DPBS and resuspended into a
single cell population before flow cytommetry on an Accuri C6 was performed. (C) Graphical
representation of the percentage of ROS positive populations in each treatment condition.
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increase in ROS positive DCFDA fluorescence occurring with no recovery time, when
compared to cells receiving DCFDA only. A gradual decline was observed at each
isolation point during the recovery period (Figure 8C). This indicates that MCF7 cells
grown in full serum media provide higher levels of ROS positive DCFDA fluorescence
when compared to MCF7 cells grown in serum free media and exposed to the same
treatments. Flow cytometry results indicate that recovery after DCFDA exposure is
unnecessary and actually lowers the amount of ROS positive DCFDA fluorescence. To
treat cells in the future I determined optimal DCFDA loading conditions would be 30
minutes in DPBS, followed immediately by scraping to isolate the cells and analysis by
flow cytometry.
Having established optimized conditions for monitoring ROS positive cells using
DCFDA, I can set out to examine whether inducing YPEL3 triggered increased ROS within
human cells. Initially I tested YPEL3 overexpression by employing MCF7 cells which
harbored either a tetracycline inducible expression vector that expressed either YPEL3,
or the LacZ gene. These cells were grown either in the presence (induced) or absence
(repressed) of 1 µg/mL tetracycline (Figure 9). When tetracycline is added to cells
harboring tetracycline inducible expression vectors gene expression is induced. The
dose of 1 µg/mL tetracycline was chosen because it had previously been shown to
trigger a physiologically relevant 8 fold induction of YPEL3 gene expression (Kelley,
2010). Before performing DCFDA/flow cytometry experiments cells were exposed to
tetracycline and RNA was isolated for quantitative PCR. MCF7 cells were used to
normalize expression. MCF7 cells expressing LacZ were employed to test the integrity of
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Figure 9: Tetracycline induced YPEL3 expression in MCF7 cells does not lead to higher
ROS production when compared to LacZ induced MCF7 cells. A) QPCR results for YPEL3
expression in MCF7 cells and MCF7 cells with inducible YPEL3 or LacZ grown in the
presence or absence of 1µg/mL tetracycline for 24 hours after which total RNA was
isolated. Y axis represents the relative expression comparing YPEL3 mRNA levels
normalized to GAPDH mRNA levels. Error bars represent 95% confidence intervals from
triplicate PCR reactions analyzing YPEL3 and GAPDH cDNA’s respectively.
B) Flow cytommetry results for MCF7 cells containing a tetracycline inducible element
expressing either YPEL3 or LacZ grown in the presence or absence of 1 µg/mL
tetracycline. MCF7 cells treated with 10 µM hydrogen peroxide for 2 hours were used
as a positive control for identifying the ROS positive cell population following DCFDA
and flow cytommetry. MCF7 cells treated only with DCFDA dye were used as a ROS
negative cell population. Cells were rinsed with DPBS, scraped into DPBS and vortexed
before analysis by an Accuri C6 flow cytometer.
C) Bar Graph representing the percent of positive ROS producing cells in each cell
population (X-axis) analyzed in Figure 9B.
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the Tet-On system. The qPCR results show a 4 fold induction of YPEL3 in the YPEL3 tet
inducible cells when grown in the absence of tetracycline and compared to MCF7 cells
(Figure 9A). This indicates that the tetracycline inducible YPEL3 promoter is not
completely repressed in the Tet-On system which may be caused by the Tet repressor
protein weakly binding the Tet operon in the absence of tetracycline, or the Tet
repressor protein not fully inhibiting transcription factors from binding the promoter
expressing YPEL3. In the presence of 1 µg/mL tetracycline the YPEL3 inducible cells
show an 8 fold induction over untreated MCF7 cells and almost twice as much
expression as YPEL3 inducible cells grown in the absence of tetracycline (Figure 9A). As
expected, the lacZ tetracycline inducible cells did not show a change in YPEL3 expression
regardless of the presence or absence of tetracycline when compared to MCF7 cells
(Figure 9A). The tetracycline inducible YPEL3 cells, which have higher YPEL3 gene
expression than control cells, do not show increased ROS levels when compared to
MCF7 cells expressing LacZ (Figure 9B and 9C). This indicates that the overexpression of
YPEL3 in MCF7 cells does not lead to an increase in ROS. It should be noted however
that the YPEL3 and LacZ infected cells show an increase in ROS positive cells when
compared to MCF7 cells (Figure 9B and 9C).
Flow cytommetry results reveal an increase in ROS production in YPEL3 and LacZ
infected cells independent of tetracycline treatment when compared to MCF7 cells
(Figure 9C). The fact that the percentage of ROS positive cells do not increase suggests
elevation of ROS in cells is the result of the viral infection, the TetR protein, or selection
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with Zeocin and Blasticidin. This approach does not provide a good system to assess
ROS levels due to high levels of ROS detection in all of the infected cells.
MCF7 cells harboring a tet inducible expression vector expressing YPEL3 were
previously shown to have no effect on ROS levels, however leaky expression, or the
phenotype of MCF7 TetR cells may increase ROS levels. Therefore an alternative
method of expressing YPEL3 in MCF7 cells was utilized, as well as exposing the cells to
an extended period of YPEL3 overexpression to determine if ROS production is a delayed
response to YPEL3 overexpression. To determine if MCF7 cells infected with YPEL3 can
increase ROS levels after infection, immortalized MCF7 cells were infected with
lentivirus expressing YPEL3, or H-RAS as a positive control (Figure 10). Cells were
selected with Zeocin (750 µg/mL) or blasticidin (6 µg/mL) for 12 days, and then
reseeded for an additional two days before RNA isolation and RT-QPCR were performed
to monitor YPEL3 levels. RT-QPCR results show that MCF7 cells infected with lentivirus
producing YPEL3 showed a 56-fold increase in YPEL3 when compared to uninfected
MCF7 cells. Interestingly YPEL3 expressing MCF7 cells also demonstrated an 11-fold
increase in p21 expression (Figure 10A). H-RAS infected MCF7 cells possessed a more
modest 4-fold increase in p21 gene expression and a 4-fold increase in YPEL3
expression, compared to MCF7 cells. RAS expression was undetectable after many
attempts to quantify mRNA levels, however overexpression of RAS has previously been
shown to increase mRNA expression of p21 through p53 (Agarwal, 2001). Under this
assumption it would appear that RAS was expressed, however the level at which it was
expressed is unknown.
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Figure 10: MCF7 cells infected with lentivirus expressing YPEL3 show increased gene
expression of YPEL3. (A) MCF7 cells were plated in complete media for 24 hours before
being infected with lentivirus expressing YPEL3 or RAS. RNA was isolated after 24 hours.
YPEL3 and p21 mRNA levels were analyzed using RT-PCR normalized to GAPDH mRNA.
Error bars represent the 95% confidence intervals resulting from triplicate assays for
both YPEL3 and GAPDH expression. (B) MCF7 cells were exposed to hydrogen peroxide
plus DCFDA, or just DCFDA, infected cells were exposed to DCFDA only, and then
scraped in DPBS. These samples were vortexed and flow cytommetry was performed.
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To assess ROS production by flow cytometry, MCF7 cells infected with lentivirus
expressing YPEL3, or H-RAS were selected for 12 days with Zeocin (750 µg/mL) or
blasticidin (6 µg/mL) and then reseeded for an additional 2 days. Infected MCF7 cells
were exposed to DCFDA (30 min) followed by scraping to isolate the cells in DPBS (1 mL)
and then vortexed to ensure a single population for flow cytometry analysis. Flow
cytometry results show infection of MCF7 cells with H-RAS and cells treated with
hydrogen peroxide show an increase in ROS production when compared to MCF7 cells
(16% and 14% Vs. 5%) (Figure 10B). MCF7 cells overexpressing YPEL3 did not show an
increase in positive ROS producing cells when compared to MCF7 cells (5% Vs. 5%)
(Figure 10B).
Having established that increased level of YPEL3 did not appear to cause an increase
of ROS in MCF7 breast cancer cells, IMR90 cells were utilized to determine if YPEL3
senescence in primary fibroblasts is dependent on ROS. IMR90 primary human diploid
fibroblast cells were utilized due to their non transformed nature, intact pathways and
ability to undergo replicative senescence, as well as oncogene induced senescence.
IMR90 cell were also utilized because an increase in ROS dependent on YPEL3 may be
related to the genetic context of the cell.
To further investigate any connections between YPEL3 and ROS, IMR90 cells were
infected with Lentivirus expressing YPEL3, or expressing H-RAS as a positive control
(Figure 11). RNA was isolated 2 days post infection and RT-QPCR performed to monitor
the levels of YPEL3 expression. RT-QPCR results show that IMR90 cells infected with
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lentivirus producing YPEL3 showed a 1000 fold increase in YPEL3 when compared to
uninfected IMR90 cells. Interestingly YPEL3 expressing IMR90 cells also demonstrated
an 8 fold increase in p21 expression, but no significant alteration in endogenous RAS
gene expression (Figure 11A). H-RAS infected IMR90 cells possessed a more modest 5fold increase in RAS gene expression compared to IMR90 cells, as well as a 10-fold
induction of p21 and a 5-fold induction of YPEL3 (Figure 11A).
Using DCFDA and flow cytometry I next examined how YPEL3 and H-RAS infection of
IMR90 cells impacted ROS activity. Interestingly, the addition of hydrogen peroxide
resulted in only a modest increase in ROS positive cells (Figure 11B, 19% Vs. 11%).
While YPEL3 overexpressing IMR90 cells showed no significant increase in ROS positive
cells (Figure 11B, 10% Vs. 11%) The inability of H-RAS to trigger increased ROS activity
(Figure 11B, 12% Vs. 11%) makes it difficult to conclude whether or not YPEL3
overexpression is capable of eliciting ROS activity in IMR90 cells. Since the H-RAS
infected cells were not selected and showed a more modest level of mRNA induction
(Figure 11A) it is possible that the failure to detect increased ROS activity as previously
reported (Moiseeva, 2009) was the result of a low transduction rate or no selection
applied. If that assumption is accepted then these results suggest YPEL3 overexpression
does not lead to increased ROS activity in IMR90 cells. These results indicate that YPEL3
does not cause an increase in ROS, and may not trigger senescence in a ROS dependant
manner in non cancerous IMR90 cells.
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Figure 11: IMR90 Cells Infected With YPEL3 Expresing Lentivirus Does Not Lead To
Increased ROS Production. (A) IMR90 cells were infected with Lentivirus expressing
YPEL3 or RAS. RNA was isolated at 24 hours. YPEL3, RAS and p21 mRNA levels were
analyzed using RT-PCR normalized to GAPDH mRNA levels. Error bars represent 95%
confidence intervals from triplicate PCR reactions analyzing YPEL3, p21, RAS and GAPDH
cDNA’s respectively. (B) Flow Cytommetry for IMR90 cells infected with YPEL3 or RAS,
as well as a negative control exposed to DCFDA (30 Min) and a positive control exposed
to DCFDA (30 Min) plus the addition of hydrogen peroxide (2 Hr). Cells were isolated by
scraping into 1mL DBPS and immediately analyzed by flow cytometry.
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V. Co-Immunoprecipitation of YPEL3-V5 Reveals Potential Bound Proteins.

Previous studies have linked increased expression of YPEL3 to cellular senescence
(Kelley, 2010 and Tuttle, 2011). However, the mechanism of senescence activation by
YPEL3 is unknown. In an attempt to discover putative binding proteins that interact
with YPEL3 proteins, a Tet-On expression system was utilized followed by coimmunoprecipitation of YPEL3 and any bound proteins. The Tet-On system allows
expression of a gene of interest in the presence of tetracycline, or its derivative
doxocycline and contains a strong constitutively active cytomegalovirus promoter which
expresses a tetracycline repressor gene that produces a tetracycline repressor protein
(TetR). The TetR protein binds to a tetracycline operon that overlaps with a second
promoter ligated to an expression gene, which in this case expresses YPEL3. The second
promoter is normally repressed by TetR, however in the presence of tetracycline the
TetR protein is released from the tet operon and transcription of YPEL3 along with a V5
epitope tag occurs. The V5 epitope tag allows us to co-immunoprecipitate YPEL3 by
binding it to anti V5 agarose beads and precipitating it from whole cell extracts.
Activation of the second promoter in the presence of tetracycline will cause
amplification of YPEL3-V5 protein levels, which can be extracted upon lysis of the cells.
In order to perform a co-immunoprecipitation the conditions under which cells are lysed
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must be optimized to conserve protein interactions and decrease the chance of protein
degradation. By utilizing anti V5 agarose beads YPEL3-V5 can be extracted along with
any YPEL3 linked proteins. The protein sequences of the co-immunoprecipitated
proteins were determined by liquid chromatography tandem mass spectrometry
analysis (LC/MS/MS) at Oregon Health and Science University. To analyze proteins by
LC/MS/MS, proteins are first enzymatically digested into peptides at Oregon Health
Science University and introduced into a mass spectrometer via a liquid chromatography
system. Once inside the mass spectrometer the peptides are fragmented to produce
MS/MS spectra. The patterns of fragmentation are matched against theoretical spectra
from a protein database and the sequence of each individual peptide is derived. Scoring
algorithms and statistical tools are then used to determine their identification and
quantity.
To determine if we were able to extract YPEL3 by co-immunoprecipitation, MCF7
cells that had previously been infected on two separate occasions with a Tet-On system
followed by infection with lentivirus expressing YPEL3 fused to a V5 epitope tag were
grown in complete media containing 10 μg/mL of tetracycline for 24 hours to induce
YPEL3 gene expression. The two separate infections were identified as Y3O, to indicate
cells created by Kelly Miller, and Y3N to indicate cells created by Dr. Steven Berberich.
Alternatively MCF7 cells were infected with a Tet-On system lacking YPEL3 or a V5 tag
(MCF7 TetR) were also subject to 10 μg/mL of tetracycline for 24 hours. Post
tetracycline exposure, MCF7 cells were scraped into 5 mL of DBPS and pelleted. After
freezing the cells (-80oC minimum of 24 hours) they were thawed and lysed in 5 volumes
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of lysis buffer components and centrifuged to separate soluble and insoluble material.
A Bradford assay was performed on the extracts to determine the protein
concentration. Protein extract (50 mg) was diluted in lysis buffer (10 mL) with the
addition of anti V5 agarose beads (40µg) and inverted overnight at 4oC before being
subjected to 3 washes to remove unbound proteins. Covalently bound proteins were
eluted from the V5 agarose beads in 6X SDS loading dye and proteins were separated on
an SDS-Page gradient gel by electrophoresis. After Western transfer, the blot was
probed for YPEL3 with a primary monoclonal V5 antibody (1:5000 for 4 hours) and a
secondary goat anti mouse antibody conjugated to horseradish peroxidase (1:2500).
Chemiluminesence analysis of the probed blot showed the presence of YPEL3 in the Y3O
and Y3N lanes between the 15-25 kDa molecular weight markers, indicating YPEL3-V5
was eluted in the co-immunoprecipitation (Figure 12). As expected, a band was not
present in the extracts not expressing YPEL3-V5 (MCF7 TetR), as indicated by the
absence of a band in lane 5 between 15-25 kDa. The higher molecular weight bands
indicate V5 antibody binding to human proteins lacking V5 antibody. This could have
been caused by insufficient blocking or too high of a primary or secondary antibody
concentration. Moving forward growth of the YPEL3 inducible cells known as YPEL3 New
or Y3N were discontinued in favor of the cells known as YPEL3 Old, or Y3O, due to a
higher level YPEL3 expression determined by qPCR after Y3O and Y3N were treated with
10µg/mL tetracycline (data not shown). In addition the protocol was optimized by
exposing the beads to an additional 3 washes in lysis buffer to remove unbound
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Figure 12: Extraction of YPEL3-V5 by co-immunoprecipitation.
MCF7 cells harboring a tetracycline expression vector expressing YPEL3-V5 (Y3O or
Y3N), or not expressing YPEL3 (TetR) were grown in DMEM minus tetracycline until
reaching 80% confluency. Tetracycline was added to the media (10 μg/mL of media) for
24 hours and the cells were scraped in5mL DPBS for pelleting. Cells were frozen then
lysed (50mM Tris pH 8.0, 5mM EDTA, 150nM NaCl, 0.5% Nonident p-40, 1mM
phenylmethanesulfonylfluoride (Sigma), 1mM Dithiothreitol (Sigma) and Protease
Inhibitor Coctail (Sigma)) and centrifuged to remove insoluble material. Protein extracts
(40 mg) were co-immunoprecipitated and eluted for separation on an SDS page gel by
electrophoresis. Proteins were transferred by Western analysis and probed with
primary V5 antibody (1:5000 for 4 hours) and secondary goat anti mouse antibody
conjugated to horseradish peroxidase (1:2500). Molecular weights were determine by
comparing to the molecular weight marker (M). Lane 2 is blank (B). Arrow is pointing to
YPEL3-V5 tagged proteins.
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proteins. A colloidal blue stain of each fraction taken after a wash indicated the absence
of unbound proteins after 6 washes (data not shown). All co-immunoprecipitation
beads from this point were washed 6 times in lysis buffer.
The ability to extract YPEL3-V5 is crucial for the discovery of potential YPEL3 bound
proteins. After extraction and separation any bands occurring in the Y3O lane that does
not occur in the TetR lane could be potential binding proteins of YPEL3 that would be
excised and analyzed by mass spectrometry. To visualize these potential bands a highly
sensitive method of protein detection known as silver staining was implemented. To
determine the best silver stain method that is mass spectrometry compatible, three
silver staining methods were compared, each using an identical amount of protein.
Protein for this analysis was obtained either from the whole cell extracts of MCF7 cells
(MCF7 TetR and Y3O) after treatment with tetracycline, or protein was eluted off of anti
V5 agarose beads after co-immunoprecipitation of whole cell extracts (Figure 13). The
Bio-Rad method developed distinct bands with little background noise and would be the
preferred method of choice; however this silver stain method is incompatible with mass
spectrometry due to the use of a strong oxidizer (Figure 13A). Method 2 had a high level
of background noise and either revealed very faint yellow bands, or was not sensitive
enough to pick up bands that appeared in the other 2 methods (Figure 13B). The lanes
appeared either clear or slightly yellow in method 2. Method 3 was nearly as free of
background noise as the Bio Rad kit method and showed an equivalent number of
visible bands (Figure 13C). This method is also compatible with mass spectrometry and
yields a high level of protein recovery for analysis because it does not cause cross linking
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A)

B)

C)

*
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Figure 13: Comparison of three Silver Stain Methods.
SDS-Page protein gels were fixed in 40% methanol and 5% acetic acid overnight on a
shaker. (A) Method 1 Bio-Rad Silver stain kit (Bio-Rad). (B) Method 2 10%
glutaraldehyde, 200 nM dithiothreitol, .1% silver nitrate. (C) Method 3 sodium
thiosulfate, .1% silver nitrate. (A, B, C) Develop with .04% formalin plus 2% sodium
carbonate. Stop development in 1% acetic acid. The molecular weight marker is
indicated by (M). Whole cell extracts were indicated as Tet-On (T) and Tet-On expressing
YPEL3 (Y3). The samples labeled (Tf and Y3f) were insoluble protein fractions not bound
to V5 agarose beads.
* The gel in method 1 is on the same scale as method 2 and 3 however it appears
smaller due it tearing during removal from the electrophoresis apparatus. The majority
of the gel that was lost was below the SDS dye front.
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of proteins and utilizes a weak oxidizer so silver ions can be easily removed before mass
spectrometry. All subsequent experiments use silver staining method 3.
To isolate potential proteins interacting with the YPEL3 protein, whole cell extracts
(TetR and Y3) of tetracycline treated cells (10 µg/mL) were co-immunoprecipitated and
bound protein was subsequently eluted by a competitively binding V5 peptide (30 min).
After the first elution, the anti V5 agarose beads were exposed to 1X SDS loading dye to
elute any additional proteins still bound to the beads (BF). The eluted fraction (EF) and
BF fraction were separated on an SDS page gel and analyzed by silver staining (Figure
14). The wells loaded with EF appear to be absent of any detectable protein, indicating
elution by competing V5 peptide may not be the best method of elution or the elution
should have been for a longer period of time. The bead fraction (BF) had two bands
appear in the Y3 lane that were absent in the Tet lane. Excision of the bands, followed
by Liquid chromatography-tandem mass spectrometry analysis revealed a larger band
near 140 kDa (Band 1) contained Mov10 (Putative Helicase), HNRL1 (Heterogeneous
nuclear ribonucleoprotein U like protein), Lima1 (Lim domain and actin binding protein)
and RBM14 (RNA binding protein 14) (Table 2). Interestingly, these proteins were not
found in any of the other analyzed bands. In addition to Band 1, another band near 60
kDa was extracted and analyzed by mass spectrometry (Figure 14). The second band
(Band 2) contained two proteins, CARM-1 (Histone Arginine Methyl Transferase) and
FA98A (isoform belonging to FAAM98A protein family), not found in any of the other
analyzed bands (Table 2).
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EF

Beads
Band 1
Band 2
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Figure 14: Secondary elution revealing 2 bands in the YPEL3 only lane. Band 1 was
between 140kDA-100kDA and band 2 between 70kDa-50kDA. MCF7 TetR and Y3O cell
extracts (40 mg) were co-immunoprecipitated with anti V5 agarose beads and YPEL3-V5
was competitively eluted from the beads after being washed 6 times to remove non
specifically bound proteins (EF). The beads were subsequently exposed to SDS loading
dye to elute any remaining proteins (Beads). The eluted proteins were separated on an
SDS Page gel by electrophoresis and stained with silver stain. Two bands (indicated by
arrows) were excised and incubated twice for 30 minutes in 1.0 mL of solution made of
acetonitrile and 100 mM ammonium bicarbonate mixed in a 1:1 ratio. After the second
washing the mixture was fully removed and the extracted bands were dried in a speed
vac.
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Under the assumption that the eluted fraction had a low level of protein due to the
inability of the competing peptide to efficiently compete off YPEL3-V5 from the beads in
30 minutes, the eluted fractions were concentrated from 160 µL to 20 µL. This also
removed any proteins below 3000 Da in size due to the concentrator’s molecular weight
cutoff. Silver stain analysis revealed a band above 50 kDa in the Y3 lane (Band 3)
however no additional bands were discovered (Figure 15, EFc). Mass spectrometry
analysis of this band determined that the majority of the protein was caused by
contamination (Table 2). The bead fraction was separated by electrophoresis on an SDS
page gel and stained by silver stain (Figure 15 Beads), which showed a similar pattern to
the bead extraction in figure 14.
To assess if an alternative method of eluting proteins from anti V5 agarose beads will
give us a higher protein yield, the extracts of treated (10 µg/mL tetracycline) MCF7 cells
(TetR and Y30) were co-immunoprecipitated by anti V5 agarose beads, however protein
was eluted by heating (75oC) the samples for 5 minutes in 1X SDS running buffer (Figure
16). Silver staining was utilized to locate variations in bands between the two samples.
After developing the gel, thick bands appeared in each lane above the 50 kDa molecular
weight marker and two additional bands appeared at 35 kDa and 25 kDa in each lane.
The only variation that occurred was a darker band in the YPEL3 expressing cells near 25
kDa. This band was also visible in MCF7 (TetR) cells, but much more faint. The
difference in band intensity does not appear to be loading related because the other
bands in each lane exhibit the same level of intensity. Extraction of the band and
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Figure 15: Band 3 located between the 50kDa and 70kDa molecular weight markers.
MCF7 TetR and Y3O cell extracts (40 mg) were co-immunoprecipitated with anti V5
agarose beads and YPEL3-V5 was competitively eluted from the beads after being
washed 6 times to remove non specifically bound proteins (EFc). The EF fractions were
concentrated from 160µL to 20 µL and SDS loading dye was added. The beads were
subsequently exposed to SDS loading dye to elute any remaining proteins (Beads). The
eluted proteins were separated on an SDS Page gel by electrophoresis and stained with
silver stain. One band (indicated by arrow) was excised and shook twice for 30 minutes
in 1.0 mL of solution made of acetonitrile and 100 mM ammonium bicarbonate mixed in
a 1:1 ratio. After the second washing the mixture was fully removed and the extracted
bands were dried in a speed vac.
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Figure 16: The fourth extracted band from immunoprecipitated material appeared
between the 25kDa and 35kDa molecular weight bands.

MCF7 TetR and Y3O cell

extracts (68.4 mg) were co-immunoprecipitated with anti V5 agarose beads and YPEL3V5 was eluted in 1X SDS running buffer after the beads were washed 6 times (EF). The
EF fractions were concentrated from 200µL to 20 µL and SDS loading dye was added.
The beads were subsequently exposed to SDS loading dye to elute any remaining
proteins (Beads). The eluted proteins were separated on an SDS Page gel by
electrophoresis and stained with silver stain. One band (indicated by arrow) was
excised and shook twice for 30 minutes in 1.0 mL of solution made of acetonitrile and
100 mM ammonium bicarbonate mixed in a 1:1 ratio. After the second washing, the
mixture was fully removed, and the extracted bands were dried in a speed vac.
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subsequent mass spectrometry analysis did not determine the presence of any potential
YPEL3 binding proteins (Table 2).
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Table 2: Liquid chromatography tandem mass spectrometry analysis (LC/MS/MS)
Band Band Band Band
1
2
3
4

Description

Accession

MW

REVERSED.

REV_Q8WZ42

3816189

2

0

0

1

Titin OS=Homo sapiens GN=TTN
PE=1 SV=2

TITIN_HUMAN

3816189

0

2

1

1

Mucin-5B OS=Homo sapiens
GN=MUC5B PE=1 SV=3

MUC5B_HUMAN

596341

0

0

2

0

Desmoplakin OS=Homo sapiens
GN=DSP PE=1 SV=3
REVERSED.

DESP_HUMAN
REV_O15417

331775
314520

2
2

8
1

15
0

7
0

Hornerin OS=Homo sapiens
GN=HRNR PE=1 SV=2

HORN_HUMAN

282391

1

1

3

1

Probable G-protein coupled receptor
179 OS=Homo sapiens GN=GPR179
PE=2 SV=2

GP179_HUMAN

257364

0

0

2

0

WDR90_HUMAN
REV_P02452

187438
138943

1
0

0
0

2
0

1
2

SF3B3_HUMAN

135578

4

0

0

0

Myosin-Ib OS=Homo sapiens
GN=MYO1B PE=1 SV=3

MYO1B_HUMAN

131986

10

0

0

0

Myosin-Ic OS=Homo sapiens
GN=MYO1C PE=1 SV=4

MYO1C_HUMAN

121683

42

0

0

0

Myosin-Id OS=Homo sapiens
GN=MYO1D PE=1 SV=2

MYO1D_HUMAN

116203

12

0

0

0

Probable ATP-dependent RNA
helicase DHX36 OS=Homo sapiens
GN=DHX36 PE=1 SV=2

DHX36_HUMAN

114761

2

0

0

0

Desmoglein-1 OS=Homo sapiens
GN=DSG1 PE=1 SV=2

DSG1_HUMAN

113749

2

2

7

1

Putative helicase MOV-10 OS=Homo
sapiens GN=MOV10 PE=1 SV=2

MOV10_HUMAN

113672

5

0

0

0

Alpha-actinin-4 OS=Homo sapiens
GN=ACTN4 PE=1 SV=2

ACTN4_HUMAN

104855

2

0

0

0

DSC1_HUMAN

99988

1

2

5

2

HNRL1_HUMAN

95740

32

0

0

0

ILF3_HUMAN

95339

2

0

0

0

WD repeat-containing protein 90
OS=Homo sapiens GN=WDR90
PE=1 SV=2
REVERSED.
Splicing factor 3B subunit 3
OS=Homo sapiens GN=SF3B3 PE=1
SV=4

Desmocollin-1 OS=Homo sapiens
GN=DSC1 PE=1 SV=2
Heterogeneous nuclear
ribonucleoprotein U-like protein 1
OS=Homo sapiens GN=HNRNPUL1
PE=1 SV=2
Interleukin enhancer-binding factor 3
OS=Homo sapiens GN=ILF3 PE=1
SV=3
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Accession

Pre-rRNA-processing protein TSR1
homolog OS=Homo sapiens
GN=TSR1 PE=1 SV=1

TSR1_HUMAN

91811

2

0

0

0

Transcription intermediary factor 1beta OS=Homo sapiens GN=TRIM28
PE=1 SV=5

TIF1B_HUMAN

88551

4

0

0

0

LIMA1_HUMAN

85227

9

0

0

0

PIGR_HUMAN
REV_P33897

83285
82938

1
0

3
0

8
2

0
0

Junction plakoglobin OS=Homo
sapiens GN=JUP PE=1 SV=3

PLAK_HUMAN

81746

0

4

8

3

Caprin-1 OS=Homo sapiens
GN=CAPRIN1 PE=1 SV=2

CAPR1_HUMAN

78367

3

0

0

0

Lactotransferrin OS=Homo sapiens
GN=LTF PE=1 SV=6

TRFL_HUMAN

78183

3

10

38

2

Polyubiquitin-C OS=Homo sapiens
GN=UBC PE=1 SV=2

UBC_HUMAN

77030

1

2

2

2

Protein-glutamine gammaglutamyltransferase E OS=Homo
sapiens GN=TGM3 PE=1 SV=4

TGM3_HUMAN

76633

1

1

5

3

Uncharacterized protein C6orf222
OS=Homo sapiens GN=C6orf222
PE=2 SV=1

CF222_HUMAN

71931

2

0

0

1

RNA-binding protein 14 OS=Homo
sapiens GN=RBM14 PE=1 SV=2

RBM14_HUMAN

69493

23

0

0

0

SERUM ALBUMIN PRECURSOR
[Homo sapiens].

CONT_017

69368

6

5

20

8

Serum albumin OS=Homo sapiens
GN=ALB PE=1 SV=2

ALBU_HUMAN

69368

6

5

20

8

SERUM ALBUMIN PRECURSOR
[Bos taurus].

CONT_016

69271

6

4

8

6

DDX5_HUMAN

69149

1

2

0

0

K2C1_HUMAN

66040

111

178

314

177

(S43646) cytokeratin 2, CK 2 [human,
epidermis, Peptide, 645 aa].

CONT_064

65912

53

80

136

73

KERATIN, TYPE II CYTOSKELETAL
2 EPIDERMAL (CYTOKERATIN 2E)
(K2E) (CK 2E) [Homo sapiens].

CONT_072

65866

53

80

136

73

LIM domain and actin-binding protein
1 OS=Homo sapiens GN=LIMA1
PE=1 SV=1
Polymeric immunoglobulin receptor
OS=Homo sapiens GN=PIGR PE=1
SV=4
REVERSED.

Probable ATP-dependent RNA
helicase DDX5 OS=Homo sapiens
GN=DDX5 PE=1 SV=1
Keratin, type II cytoskeletal 1
OS=Homo sapiens GN=KRT1 PE=1
SV=6
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MW

Band Band Band Band
1
2
3
4

Description

Accession

Histone-arginine methyltransfeRASe
CARM1 OS=Homo sapiens
GN=CARM1 PE=1 SV=3
albumin [Bos primigenius taurus].

CARM1_HUMAN
CONT_015

65855
65798

0
6

8
4

0
8

0
6

keratin, 67K type II cytoskeletal
[Homo sapiens].

CONT_143

65495

80

114

208

112

SEMG2_HUMAN

65445

1

1

3

0

K22E_HUMAN

65434

57

87

145

78

CONT_142

64449

3

6

16

14

K2C3_HUMAN

64418

3

6

16

14

KPRP_HUMAN

64137

1

4

14

3

TNR8_HUMAN

63748

0

2

0

0

K2C5_HUMAN

62379

22

36

68

54

K1C9_HUMAN

62065

59

104

185

93

K2C1B_HUMAN

61902

12

22

33

16

P4HA1_HUMAN

61050

0

2

0

0

CONT_133

60068

26

42

87

70

K2C6B_HUMAN

60068

26

42

87

70

CONT_129

60046

24

35

72

70

K2C6A_HUMAN

60046

24

35

72

70

CATA_HUMAN

59757

0

0

2

0

Semenogelin-2 OS=Homo sapiens
GN=SEMG2 PE=1 SV=1
Keratin, type II cytoskeletal 2
epidermal OS=Homo sapiens
GN=KRT2 PE=1 SV=2
keratin, 65K type II cytoskeletal
[Homo sapiens].
Keratin, type II cytoskeletal 3
OS=Homo sapiens GN=KRT3 PE=1
SV=3
Keratinocyte proline-rich protein
OS=Homo sapiens GN=KPRP PE=1
SV=1
Tumor necrosis factor receptor
superfamily member 8 OS=Homo
sapiens GN=TNFRSF8 PE=1 SV=1
Keratin, type II cytoskeletal 5
OS=Homo sapiens GN=KRT5 PE=1
SV=3
Keratin, type I cytoskeletal 9
OS=Homo sapiens GN=KRT9 PE=1
SV=3
Keratin, type II cytoskeletal 1b
OS=Homo sapiens GN=KRT77 PE=1
SV=3
Prolyl 4-hydroxylase subunit alpha-1
OS=Homo sapiens GN=P4HA1 PE=1
SV=2
KERATIN, TYPE II CYTOSKELETAL
6F (CYTOKERATIN 6F) (CK 6F)
(K6F KERATIN) [Homo sapiens].
Keratin, type II cytoskeletal 6B
OS=Homo sapiens GN=KRT6B PE=1
SV=5
KERATIN, TYPE II CYTOSKELETAL
6A (CYTOKERATIN 6A) (CK 6A)
(K6A KERATIN) [Homo sapiens].
Keratin, type II cytoskeletal 6A
OS=Homo sapiens GN=KRT6A PE=1
SV=3
Catalase OS=Homo sapiens
GN=CAT PE=1 SV=3
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MW

Band Band Band Band
1
2
3
4

Description

Description
Keratin, type II cytoskeletal 73
OS=Homo sapiens GN=KRT73 PE=1
SV=1
SWI/SNF-related matrix-associated
actin-dependent regulator of
chromatin subfamily D member 2
OS=Homo sapiens GN=SMARCD2
PE=1 SV=3
Keratin, type I cytoskeletal 10
OS=Homo sapiens GN=KRT10 PE=1
SV=6
SWI/SNF-related matrix-associated
actin-dependent regulator of
chromatin subfamily D member 1
OS=Homo sapiens GN=SMARCD1
PE=1 SV=2
Keratin, type II cytoskeletal 79
OS=Homo sapiens GN=KRT79 PE=1
SV=2
Keratin, type II cytoskeletal 4
OS=Homo sapiens GN=KRT4 PE=1
SV=4
KERATIN, TYPE II CYTOSKELETAL
4 (CYTOKERATIN 4) (K4) (CK4)
[Homo sapiens].
keratin 10, type I, epidermal [Homo
sapiens].
Keratin, type II cytoskeletal 78
OS=Homo sapiens GN=KRT78 PE=1
SV=2
Protein FAM98A OS=Homo sapiens
GN=FAM98A PE=1 SV=1
Keratin 8 - human [Homo sapiens].
Keratin, type II cytoskeletal 8
OS=Homo sapiens GN=KRT8 PE=1
SV=7
KERATIN, TYPE I CYTOSKELETAL
12 (CYTOKERATIN 12) [Homo
sapiens].
Keratin, type I cytoskeletal 12
OS=Homo sapiens GN=KRT12 PE=1
SV=1
RNA-binding protein FUS OS=Homo
sapiens GN=FUS PE=1 SV=1
Keratin, type I cytoskeletal 14
OS=Homo sapiens GN=KRT14 PE=1
SV=4
Keratin, type I cytoskeletal 16
OS=Homo sapiens GN=KRT16 PE=1
SV=4

Accession

MW

Band Band Band Band
1
2
3
4

K2C73_HUMAN

58924

3

6

11

6

SMRD2_HUMAN

58922

0

7

0

0

K1C10_HUMAN

58828

63

91

172

80

SMRD1_HUMAN

58234

0

2

0

0

K2C79_HUMAN

57837

5

11

28

26

K2C4_HUMAN

57286

6

10

13

7

CONT_119

57266

6

10

13

7

CONT_046

57248

50

75

136

64

K2C78_HUMAN

56867

4

7

13

9

FA98A_HUMAN
CONT_103

55402
53705

0
4

10
11

0
8

0
4

K2C8_HUMAN

53705

4

11

8

4

CONT_165

53512

6

7

11

3

K1C12_HUMAN

53512

6

7

11

3

FUS_HUMAN

53427

2

1

1

2

K1C14_HUMAN

51562

27

39

60

45

K1C16_HUMAN

51269

22

27

52

38

77

Description
type I keratin 16 [human, epidermal
keratinocytes, Peptide, 473 aa].
Keratin, type II cytoskeletal 80
OS=Homo sapiens GN=KRT80 PE=1
SV=2

Accession

MW

Band Band Band Band
1
2
3
4

CONT_156

51239

22

27

52

38

K2C80_HUMAN

50526

1

0

5

1

EF1A3_HUMAN

50186

0

0

2

0

EF1A1_HUMAN

50142

0

0

2

0

K1C27_HUMAN

49823

6

13

19

9

K1C13_HUMAN

49589

5

15

22

9

KHDR1_HUMAN

48228

0

3

0

0

CONT_094

48107

15

21

35

44

K1C17_HUMAN

48107

15

21

35

44

Serpin B12 OS=Homo sapiens
GN=SERPINB12 PE=1 SV=1

SPB12_HUMAN

46277

0

2

1

0

Serpin B3 OS=Homo sapiens
GN=SERPINB3 PE=1 SV=2

SPB3_HUMAN

44566

0

1

5

0

Actin, cytoplasmic 2 OS=Homo
sapiens GN=ACTG1 PE=1 SV=1

ACTG_HUMAN

41794

2

7

49

2

Actin, cytoplasmic 1 OS=Homo
sapiens GN=ACTB PE=1 SV=1

ACTB_HUMAN

41738

2

7

49

2

Fructose-bisphosphate aldolase A
OS=Homo sapiens GN=ALDOA
PE=1 SV=2

ALDOA_HUMAN

39421

0

0

2

0

Annexin A1 OS=Homo sapiens
GN=ANXA1 PE=1 SV=2

ANXA1_HUMAN

38715

0

0

3

0

Annexin A2 OS=Homo sapiens
GN=ANXA2 PE=1 SV=2

ANXA2_HUMAN

38605

0

2

6

3

Ig alpha-1 chain C region OS=Homo
sapiens GN=IGHA1 PE=1 SV=2

IGHA1_HUMAN

37656

4

0

6

2

Ig alpha-2 chain C region OS=Homo
sapiens GN=IGHA2 PE=1 SV=3

IGHA2_HUMAN

36527

2

0

4

1

Putative elongation factor 1-alpha-like
3 OS=Homo sapiens GN=EEF1A1P5
PE=5 SV=1
Elongation factor 1-alpha 1
OS=Homo sapiens GN=EEF1A1
PE=1 SV=1
Keratin, type I cytoskeletal 27
OS=Homo sapiens GN=KRT27 PE=1
SV=2
Keratin, type I cytoskeletal 13
OS=Homo sapiens GN=KRT13 PE=1
SV=4
KH domain-containing, RNA-binding,
signal transduction-associated protein
1 OS=Homo sapiens GN=KHDRBS1
PE=1 SV=1
KERATIN, TYPE I CYTOSKELETAL
17 (CYTOKERATIN 17) (K17) (CK
17) (39.1) (VERSION 1) [Homo
sapiens].
Keratin, type I cytoskeletal 17
OS=Homo sapiens GN=KRT17 PE=1
SV=2
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Accession

Glyceraldehyde-3-phosphate
dehydrogenase OS=Homo sapiens
GN=GAPDH PE=1 SV=3

G3P_HUMAN

36054

2

4

8

4

Arginase-1 OS=Homo sapiens
GN=ARG1 PE=1 SV=2

ARGI1_HUMAN

34736

1

1

2

1

Zinc-alpha-2-glycoprotein OS=Homo
sapiens GN=AZGP1 PE=1 SV=2

ZA2G_HUMAN

34260

1

1

4

1

40S ribosomal protein SA OS=Homo
sapiens GN=RPSA PE=1 SV=4

RSSA_HUMAN

32855

0

0

2

0

TPM2_HUMAN

32852

0

0

2

0

TPM3_HUMAN

32820

0

0

2

0

TPM1_HUMAN

32710

0

0

2

0

Tropomyosin beta chain OS=Homo
sapiens GN=TPM2 PE=1 SV=1
Tropomyosin alpha-3 chain
OS=Homo sapiens GN=TPM3 PE=1
SV=1
Tropomyosin alpha-1 chain
OS=Homo sapiens GN=TPM1 PE=1
SV=2
Tropomyosin alpha-4 chain
OS=Homo sapiens GN=TPM4 PE=1
SV=3

MW

Band Band Band Band
1
2
3
4

Description

TPM4_HUMAN

28523

0

0

2

0

Caspase-14 OS=Homo sapiens
GN=CASP14 PE=1 SV=2

CASPE_HUMAN

27681

1

1

4

3

Polyubiquitin-B OS=Homo sapiens
GN=UBB PE=1 SV=1

UBB_HUMAN

25763

1

2

2

2

BETA CASEIN PRECURSOR [Bos
taurus].

CONT_021

25108

2

0

4

0

ALPHA-S1 CASEIN PRECURSOR
[Bos taurus].
TRYPSIN PRECURSOR [Sus scrofa].

CONT_019
CONT_010

24530
24410

1
87

1
76

7
64

1
77

Peroxiredoxin-2 OS=Homo sapiens
GN=PRDX2 PE=1 SV=5

PRDX2_HUMAN

21893

0

3

0

2

Ubiquitin-40S ribosomal protein S27a
OS=Homo sapiens GN=RPS27A
PE=1 SV=2

RS27A_HUMAN

17966

1

2

2

2

Prolactin-inducible protein OS=Homo
sapiens GN=PIP PE=1 SV=1

PIP_HUMAN

16573

1

1

4

0

Lysozyme C OS=Homo sapiens
GN=LYZ PE=1 SV=1

LYSC_HUMAN

16538

4

5

8

2

Cystatin-S OS=Homo sapiens
GN=CST4 PE=1 SV=3

CYTS_HUMAN

16215

1

0

2

0

Proline-rich protein 4 OS=Homo
sapiens GN=PRR4 PE=1 SV=3

PROL4_HUMAN

15098

0

2

1

0

Galectin-7 OS=Homo sapiens
GN=LGALS7 PE=1 SV=2

LEG7_HUMAN

15076

0

0

2

1

Ubiquitin-60S ribosomal protein L40
OS=Homo sapiens GN=UBA52 PE=1
SV=2

RL40_HUMAN

14729

1

2

2

2
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MW

Band Band Band Band
1
2
3
4

Description

Accession

Protein S100-A9 OS=Homo sapiens
GN=S100A9 PE=1 SV=1

S10A9_HUMAN

13243

0

5

6

5

Ig kappa chain C region OS=Homo
sapiens GN=IGKC PE=1 SV=1

IGKC_HUMAN

11610

1

2

7

1

Dermcidin OS=Homo sapiens
GN=DCD PE=1 SV=2

DCD_HUMAN

11285

12

19

27

24

Protein S100-A8 OS=Homo sapiens
GN=S100A8 PE=1 SV=1

S10A8_HUMAN

10836

4

2

8

5

Promega trypsin artifact 5 K to R
mods (2239.1, 2914)(1987, 2003).
angiotensin I [Homo sapiens].

CONT_005
CONT_009

5561
1297

15
17

16
14

14
14

18
11

Table 2: Liquid chromatography-tandem mass spectrometry analysis
Analysis of 4 isolated bands reveals potential proteins that may bind to YPEL3.
Emphasis on certain proteins was based on their number of hits in each sample, as well
as their molecular weight corresponding to the excised bands. Proteins listed in normal
font are not specific to a sample, do not correlate with the molecular weight of the
excised band, have a very low hit number, or may not impact senescence. The band
numbers above the protein hit number columns correlate to the excised bands.
Proteins highlighted blue correlate to a high level of protein specificity for a certain
band. Analysis was performed at Oregon Health and Science University. Abreviations:
OS = Organism, GN= Gene Name, PE= Evidence at the Protein Level, SV= Sequence
Version.
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VI.Discussion
YPEL3 gene expression is repressed in prostate cancer cells by testosterone.
Estrogen has been implicated in estrogen receptor positive breast cancer as a pro
growth steroid hormone leading to cell proliferation. A connection was established
between estrogen and YPEL3 when the removal of estrogen, from estrogen receptor
positive breast cancer cells, caused an induction of YPEL3 gene expression (Tuttle,
2011). This discovery linked estrogen to the senescence inducing YPEL3 gene and
demonstrated a potential mechanism by which selective estrogen receptor modulators
can block breast cancer proliferation.
To build off of this previous work we expanded the research to include LnCAP
prostate cancer cells, as well as utilizing testosterone in an attempt to determine if this
steroid hormone also regulates YPEL3 expression. It was discovered that testosterone
signals proliferation in androgen receptor positive prostate cancer cells, which indicates
testosterone may have the same effect on YPEL3 expression in prostate cancer cells, as
estrogen does on ER+ breast cancer cells.
My first objective was to show the removal of hormones induce YPEL3 gene expression,
indicating that its repression is dependent on steroid hormones. Like estrogen receptor
positive breast cancer cells, growing LnCAP cells in CSS media devoid
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of steroid hormones and quantifying YPEL3 mRNA levels we were able to determine that
steroid hormones inhibit YPEL3 gene expression in LnCAP cells. Growing LnCAP cells in
CSS media with the addition of testosterone treatments repressed YPEL3 gene
expression at doses as low as 2 nM when compared to LnCAP cells grown in CSS media
only. As expected the known testosterone target gene PSA was induced in the
presence of testosterone when compared to LnCAP cells grown in CSS media only. Cells
that were harvested 24 hours after treatment did not appear to have any significant
differences in density or morphology at the time of harvest indicating a need for
additional experiments. Further experiments would need to be conducted to determine
if the removal of testosterone leads to YPEL3 dependent cellular senescence. The
length of time that 10 nM of testosterone can impact YPEL3 expression was assessed
and it was determined that at a time point after 24 hours and between 48 hours PSA
expression begins to decline, however YPEL3 is still maximally repressed at 48 hours.
This is due to testosterone having a half life between 2 and 4 hours which may indicate
that at a lower dose, testosterone can repress YPEL3, but induce PSA as well.
Quantification of the estrogen target gene pS2’s mRNA expression showed no change in
expression, indicating that testosterone is not being converted to estrogen in LnCAPs
even though LnCAPs are reported to express aromatase (Ellem, 2004). Androgen
ablation causes growth arrest in androgen receptor positive prostate cancer cells (Agus,
1999). Implications for these findings are a potential mechanism by which selective
androgen receptor modulators antagonize androgen receptors which block repression
of YPEL3 and induce growth arrest. However, additional experiments would need to be
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completed to confirm this link. Knockdown of the androgen receptor in testosterone
treated LnCAP cells grown in CSS media followed by YPEL3 gene expression analysis
would provide us with the knowledge that testosterone is repressing YPEL3 expression
in either an androgen receptor dependent, or independent manner. If YPEL3 gene
repression is dependent on the presence of testosterone and the androgen receptor, it
would be beneficial to determine if senescence is dependent on YPEL3 expression in
LnCAP prostate cancer cells. This could be accomplished by measuring β-galactosidase
activity in LnCAP cells grown in full serum media or CSS (+ or – testosterone), and
knocking down the androgen receptor in another set grown in CSS (+ or – testosterone).
If the β-galactosidase test is positive for senescence in the cells grown in CSS only this
indicates senescence is dependent on YPEL3 in the absence of testosterone or the
androgen receptor. Therapeutic effects could then be tested by administering selective
androgen receptor modulators to the LnCAP cells. Another potential target that may
regulate YPEL3 in LnCAPs is ER-β, which is the major estrogen receptor expressed in
prostate cells, due to its ability to suppress growth progression through increased levels
of p21 (Pravettoni, 2006).
YPEL3 gene expression is repressed in breast cancer cells following the addition of
testosterone.
Since testosterone has been shown to have a growth inhibiting effect on breast
cancer cells, we tested the ability of testosterone to regulate YPEL3 expression as a
potential mechanism of growth inhibition. We were able to show that in MCF7 breast
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cancer cells testosterone treatment increases YPEL3 gene expression levels.
Interestingly, we were able to show that the increase of YPEL3 gene expression is dose
dependent and also depends on the dose of estrogen present, indicating these
hormones may antagonize each other’s ability to regulate YPEL3 gene expression.
These findings suggest a mechanism and also an argument for administering a cocktail
of testosterone agonists or testosterone derivatives combined with selective estrogen
receptor modulators, as a therapy for endocrine responsive breast cancers. To
determine if senescence is testosterone and androgen receptor dependent, this can be
accomplished by measuring β-galactosidase activity in MCF7 cells grown in complete
media or CSS (+ or – testosterone) and comparing this to MCF7 cells containing a
knocking down of the androgen receptor grown, also in CSS (+ or – testosterone).
Further analysis of YPEL3 gene expression in the presence of steroid hormones could
move toward analyzing the effects of progesterone. When bound to estrogen, estrogen
receptor α can increase gene expression of the progesterone receptor (Kastner, 1990).
This increase in progesterone receptor expression plus the addition of progesterone can
either, evoke cell cycle progression, or cause cellular differentiation (Alkhalaf, 2003).
Transient pulses of progesterone regulate these two counteracting functions in breast
cancer cells by evoking cell cycle progression for the first cycle and arresting cells at the
G1 /S checkpoint of the second cycle to allow differentiation (Owen, 1998).
Differentiation continues until progesterone is degraded and the process repeats
(Owen, 1998). Progesterone accomplishes this by initially upregulating p21 gene
expression through the transcription factor sp1 (Owen, 1998). This biphasic effect of
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progesterone is antagonized by the ability of the ER-α which suppresses p21 activity
(Brekman, 2011). This pathway appears to have the potential to respond to endocrine
therapy and it has an important link to estrogen receptors, indicating its use as a
potential biomarker.
Increased levels of YPEL3 gene expression does not trigger increased ROS levels
Reactive oxygen species play a major signaling role in the event of cellular stresses.
Replicative senescence, DNA damage response and oncogene mediated senescence all
lead to the activation of p53 which is capable of activating p21 and causing growth
arrest. Increased expression of p21 increases the cellular levels of ROS in a feedback
mechanism to stabilize p53 activation and cause the cell to enter permanent senescence
(Passos, 2010). Another target gene of p53 that mediates cellular senescence is YPEL3
(Kelley, 2010).
Conditions were first optimized to detect hydrogen peroxide (H2O2) in MCF7 cells
which allows us to determine the threshold that separates cells exhibiting DCFDA
fluroescence (positive) from those that do not (negative). This assessment of conditions
includes treatments of MCF7 cells with hydrogen peroxide (2 Hr), followed by DCFDA
exposure (30 Min), rather than preloading DCFDA at the time of peroxide treatment.
Lower levels of fluorescence in the preloaded MCF7 cells could potentially be caused by
oxidation of DCFDA outside of the cells which changes its charge and causes it to
become impermeable to the cell membrane.
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Trypsinizing cells for flow cytometry analysis causes an increased level of ROS
production and clumping when compared to scraping in DPBS. This may be caused by
an extended length of time that the cells were exposed to trypsin, however scraping in
DPBS was used in future isolations. Allowing the MCF7 cells a period of exposure to full
serum media after hydrogen peroxide and DCFDA exposure should in theory cause
higher levels of DCFDA detections due to reestablishing growth factors in the media that
signal metabolism. Counter to this rational, MCF7 cells recovering in full serum media or
serum free media actually showed the same pattern of decline in DCFDA fluorescence
detection when compared. Declining fluorescence could be attributed to the ability of
catalase to convert hydrogen peroxide to oxygen and water, which would leave less to
oxidize DCFDA to DCF, or it may be caused by the ability of fluorescent DCF to leak out
of live cells and be washed away in DPBS at the time of harvest (Chen, 2003).
Overexpression of YPEL3 in MCF7 cells controlled by a Tet-On system showed by RTqPCR an increase in YPEL3 gene expression in the absence of tetracycline and an even
higher increase when tetracycline was present when compared to MCF7 cells. This
increase in YPEL3 expression was not seen in Tet-On cells expressing LacZ. Treatment
with DCFDA showed an increase in ROS levels when compared to MCF7 cells in the
absence of tetracycline, however this level remained the same when tetracycline was
added. This would suggest that the lower level of YPEL3 expression in the cells growth
without tetracycline treatment is sufficient to maximally activate ROS production.
However the LacZ expressing Tet-On MCF7 cells expressed the same levels of ROS
production indicating that a component of the Tet-On system may lead to ROS
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production. This increase in ROS could also be caused by the cells reaching confluency
and senescing, or cell culture conditions. However, this is unlikely due to the MCF7 cells
not having high fluorescence indicating ROS because all cells were subject to the same
conditions.
Since the Tet-On system left us with potentially ambiguous results regarding ROS
production, alternatively, MCF7 cells were infected with lentivius expressing YPEL3,
selected, and hydrogen peroxide levels were measured 2 days post selection. Although
a 56-fold induction of YPEL3 gene expression was shown, we were unable to detect an
increase in the levels of hydrogen peroxide, relative to MCF7 cells, by flow cytometry
analysis, as well as by fluorescent microscopy of DCFDA treated cells counterstained
with Hoechst stain. We were able to see an increase in ROS levels by flow cytometry
and fluorescent imaging when MCF7 cells express H-RAS. However this could be caused
by p21 since RAS levels were undetermined by RT-QPCR analysis.
To assess the potential of YPEL3 everexpresion to produce ROS in another cell line,
IMR90 cells were utilized. IMR90 primary human diploid fibroblast cells were utilized
due to their non transformed nature and ability to undergo replicative senescence, as
well as oncogene induced senescence. Assessing IMR90 cells expressing YPEL3 for ROS
production, we see that there is not an increase in ROS levels when compared to
untreated MCF7 cells. Surprisingly we did not see an increase in ROS levels when IMR90
cells were infected with H-RAS, however, this could be related to using cells that were
not selected after infection. This would indicate a low level of infection, which would
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correlate to the low levels of RAS induction seen by RT-QPCR. Surprisingly YPEL3 and HRAS infected cells exhibited 8 and 10 fold increases of p21 respectively. H-RAS
expression also caused a 5 fold increase in YPEL3 expression.
Potential Proteins that Interact With YPEL3 Proteins.
Since YPEL3 may function as a tumor suppressor activating senescence, it is beneficial
to discover putative proteins which interact with YPEL3 proteins. By inducing expression
of YPEL3-V5 in MCF7 cells and lysing the cells to make whole cell extracts, we were able
to extract YPEL3 and any potential YPEL3 bound proteins by co-immunoprecipitation
with anti V5 agarose beads. Analysis of co-immunoprecipitated proteins by western
blot analysis with V5 antibody showed YPEL3 bands between 15-25 kDa in the expected
lanes indicating we were able to extract the 18 kDa YPEL3-V5 protein from the whole
cell extracts (Figure 12).
After optimization of silver staining methods we were able to extract 4 bands not
found in MCF7 cells. The bands were analyzed by Liquid chromatography-mass
spectrometry, compared against a database of protein sequences and the number of
times the sequence appears in the extracted band determines its relevance. After
elimination of known contaminating bands and reverse sequences from the results we
ended up with 79 potential proteins; however some of these may still may be caused by
contamination during handling of the samples. Of the four extracted bands analyzed by
mass spectrometry, 3 of the 4 provided useable results, with band 3 composed of
mostly contamination. Two of the bands had relatively high hit numbers for proteins
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that correspond to the molecular weight where the protein bands were excised from
the gels. Gel 1 had bands extracted near 140 kDa as well as 70 kDa. Potential proteins
that had high hit levels and may correspond to the 140 kDa band includes MOV10,
HNRL1, and RBM14. A potential protein corresponding to the 70 kDa band was CARM1.
The inability to detect more proteins in bands 1 and 2, and the inability to detect
proteins in bands 3 and 4 could be due to rapid degradation of YPEL3, or due to low
affinity or transient transactions that are not conserved outside of a cells physiological
state.
Expression of co-activator associated arginine methyl transferase (CARM-1) had
previously been shown in estrogen receptor positive MCF7 cells to slow the rate cell
growth in an estrogen dependent manner by associating with estrogen receptor α and
upregulating expression of the negative cell cycle regulators p21 and p27 (Al-Dhaheri,
2011). CARM-1’s ability to increase p21 and p27 causes growth arrest by blocking cell
cycle entry into S phase (Al-Dhaheri, 2011) Interestingly it was also found to relieve
estrogen dependent repression of approximately 56% of estrogen repressed genes (AlDhaheri, 2011). This implicates CARM-1 as having a potential role in inhibiting estrogen
receptor α’s ability to repress YPEL3 which would trigger growth arrest.
MOV10 is a putative RNA helicase which has been implicated as a novel telomere
associated protein that is essential for telomerase activity in transformed cells (Wang,
2010). Telomerase activity will extend the length of telomeres and inhibit replicative
senescence in cancer cells. RNA helicases can also modulate the structure of critical
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RNA molecules and make them available for processing which leads to protein
expression (Wang, 2010). If YPEL3 has the ability to bind to MOV10 it could potentially
inhibit its ability to recruit telomerase to the telomeres which would lead to telomere
degradation and replicative senescence (Wang, 2010).
HNRL1 and RNA binding protein 14 have functions that have not been fully elucidated
and very little is known about them. HNRL1 is a splice variant of N-Methyl-D-aspartate
receptor. N-Methyl-D-aspartate receptor belongs to a subcategory of post-synaptic
ionotropic glutamate receptors which are important for sodium and calcium ion entry
into the neurons. Overstimulation of these receptors has been associated with chronic
neurodegenerative conditions due to elevations of calcium concentrations in neurons
(Camacho, 2002).
RNA binding protein 14 has been shown to interact with RISC loading complex
subunit TARBP2 (Melo, 2009). Inactivation of TARBP2 causes destabilization of the
DICER1 protein which leads to tumor formation and defects in the expression of mature
miRNA, while activation of TARBP2 inhibits tumors (Melo, 2009).
Conclusion
The goals of this thesis were to expand on the impact that hormones have on YPEL3
gene expression, to determine if YPEL3 has an impact on reactive oxygen species
generation and to identify potential proteins that bind to YPEL3 proteins. It was
demonstrated that testosterone regulation of YPEL3 is tissue type dependent.
Testosterone has an inhibitory effect on YPEL3 gene expression in androgen receptor
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positive prostate cancer cells and triggers expression of the YPEL3 gene in androgen
receptor positive breast cancer cells. Also demonstrated were the counteracting
effects on YPEL3 gene expression by combined testosterone and estrogen treatments.
Progesterone did not have an effect on YPEL3 gene expression.
Increasing YPEL3 levels did not demonstrate an increase in reactive oxygen species
levels in breast cancer cells, or primary diploid human fibroblasts, indicating YPEL3 must
mediate cellular senescence in a ROS independent manner. Co-immunoprecipitation
and LC/MS/MS analysis of proteins found 79 potential binding proteins, however this
was narrowed down to four potential proteins due to their high frequency levels, their
molecular weight corresponding to the size of the excised band and having a potential
senescence function. The potential proteins discovered were MOV10, HNRL1, RBM14
and CARM1. Taken together, these findings aim to provide mechanisms of YPEL3 gene
expression that may be targeted in endocrine therapy, as well as identifying potential
YPEL3 binding proteins that may help us understand the function of YPEL3 better and
facilitate the discovery of how it causes cellular senescence.
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